{ "instance": { "gmab-20220630x6k.htm gmab-20220630xex99d1.htm": { "axisCustom": 3, "axisStandard": 13, "contextCount": 107, "dts": { "calculationLink": { "local": [ "gmab-20220630_cal.xml" ] }, "definitionLink": { "local": [ "gmab-20220630_def.xml" ] }, "inline": { "local": [ "gmab-20220630x6k.htm", "gmab-20220630xex99d1.htm" ] }, "labelLink": { "local": [ "gmab-20220630_lab.xml" ] }, "presentationLink": { "local": [ "gmab-20220630_pre.xml" ] }, "schema": { "local": [ "gmab-20220630.xsd", "reference-2009-12-16.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 376, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 8, "total": 8 }, "keyCustom": 45, "keyStandard": 96, "memberCustom": 32, "memberStandard": 15, "nsprefix": "gmab", "nsuri": "http://www.genmab.com/20220630", "report": { "R1": { "firstAnchor": null, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://www.genmab.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": null }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - Share-Based Instruments", "role": "http://www.genmab.com/role/DisclosureShareBasedInstruments", "shortName": "Share-Based Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - Related Parties", "role": "http://www.genmab.com/role/DisclosureRelatedParties", "shortName": "Related Parties", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - Leases", "role": "http://www.genmab.com/role/DisclosureLeases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - Subsequent Events to the Balance Sheet Date", "role": "http://www.genmab.com/role/DisclosureSubsequentEventsToBalanceSheetDate", "shortName": "Subsequent Events to the Balance Sheet Date", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw", "decimals": null, "first": true, "lang": "en-US", "name": "gmab:DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20102 - Disclosure - Basis of Presentation (Policies)", "role": "http://www.genmab.com/role/DisclosureBasisOfPresentationPolicies", "shortName": "Basis of Presentation (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw", "decimals": null, "first": true, "lang": "en-US", "name": "gmab:DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30203 - Disclosure - Revenue (Tables)", "role": "http://www.genmab.com/role/DisclosureRevenueTables", "shortName": "Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw", "decimals": null, "first": true, "lang": "en-US", "name": "gmab:DisclosureOfMarketableSecuritiesByCurrencyTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30303 - Disclosure - Financial Instruments (Tables)", "role": "http://www.genmab.com/role/DisclosureFinancialInstrumentsTables", "shortName": "Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw", "decimals": null, "first": true, "lang": "en-US", "name": "gmab:DisclosureOfMarketableSecuritiesByCurrencyTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw", "decimals": null, "first": true, "lang": "en-US", "name": "gmab:DisclosureOfFinanceIncomeExpensesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30403 - Disclosure - Financial Income and Expenses (Tables)", "role": "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesTables", "shortName": "Financial Income and Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw", "decimals": null, "first": true, "lang": "en-US", "name": "gmab:DisclosureOfFinanceIncomeExpensesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30503 - Disclosure - Share-Based Instruments (Tables)", "role": "http://www.genmab.com/role/DisclosureShareBasedInstrumentsTables", "shortName": "Share-Based Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw", "decimals": null, "first": true, "lang": "en-US", "name": "gmab:DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30703 - Disclosure - Leases (Tables)", "role": "http://www.genmab.com/role/DisclosureLeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw", "decimals": null, "first": true, "lang": "en-US", "name": "gmab:DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_voh1lJjNhUCZyLqqP0N5aw", "decimals": "-6", "first": true, "lang": null, "name": "ifrs-full:Revenue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - STATEMENTS OF COMPREHENSIVE INCOME", "role": "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome", "shortName": "STATEMENTS OF COMPREHENSIVE INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_voh1lJjNhUCZyLqqP0N5aw", "decimals": "-6", "first": true, "lang": null, "name": "ifrs-full:Revenue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "p", "ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory", "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg", "decimals": "INF", "first": true, "lang": null, "name": "gmab:IfrsNumberOfReportingUnits", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_d-Yn30W8q0CdLFqZ4zWe8g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40101 - Disclosure - Basis of Presentation (Details)", "role": "http://www.genmab.com/role/DisclosureBasisOfPresentationDetails", "shortName": "Basis of Presentation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory", "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg", "decimals": "INF", "first": true, "lang": null, "name": "gmab:IfrsNumberOfReportingUnits", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_d-Yn30W8q0CdLFqZ4zWe8g", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw", "decimals": "-6", "first": true, "lang": null, "name": "ifrs-full:RevenueFromContractsWithCustomers", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40201 - Disclosure - Revenue (Details)", "role": "http://www.genmab.com/role/DisclosureRevenueDetails", "shortName": "Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw", "decimals": "-6", "first": true, "lang": null, "name": "ifrs-full:RevenueFromContractsWithCustomers", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "As_Of_6_30_2022_ifrs-full_ExternalCreditGradesAxis_gmab_TripleaRatingMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CreditRiskMember_MchtLzCh3Uufn_bh-7kpNA", "decimals": "4", "first": true, "lang": null, "name": "gmab:PercentageOfMarketableSecurities", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_ydC7mNX6akalcP_kj1H8wg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - Financial Instruments - Financial Risk (Details)", "role": "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails", "shortName": "Financial Instruments - Financial Risk (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "As_Of_6_30_2022_ifrs-full_ExternalCreditGradesAxis_gmab_TripleaRatingMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CreditRiskMember_MchtLzCh3Uufn_bh-7kpNA", "decimals": "4", "first": true, "lang": null, "name": "gmab:PercentageOfMarketableSecurities", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_ydC7mNX6akalcP_kj1H8wg", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "As_Of_6_30_2022_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_MarketableSecuritiesMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_gMTFg1fkaU-2kMTWZGvA2A", "decimals": "-6", "first": true, "lang": null, "name": "ifrs-full:FinancialAssets", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40302 - Disclosure - Financial Instruments - Fair Value Measurement (Details)", "role": "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails", "shortName": "Financial Instruments - Fair Value Measurement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "As_Of_6_30_2022_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_MarketableSecuritiesMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_gMTFg1fkaU-2kMTWZGvA2A", "decimals": "-6", "first": true, "lang": null, "name": "ifrs-full:FinancialAssets", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg", "decimals": "-6", "first": true, "lang": null, "name": "ifrs-full:InvestmentAccountedForUsingEquityMethod", "reportCount": 1, "unitRef": "Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40303 - Disclosure - Financial Instruments - Other Investments (Details)", "role": "http://www.genmab.com/role/DisclosureFinancialInstrumentsOtherInvestmentsDetails", "shortName": "Financial Instruments - Other Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "As_Of_6_30_2022_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_CurevacCollaborationMember_qc8QNPN5vUSdmz2Y_v8bjg", "decimals": "-6", "lang": null, "name": "ifrs-full:InvestmentAccountedForUsingEquityMethod", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "gmab:DisclosureOfFinanceIncomeExpensesTableTextBlock", "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw", "decimals": "-6", "first": true, "lang": null, "name": "gmab:InterestAndOtherFinancialIncome", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - Financial Income and Expenses (Details)", "role": "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails", "shortName": "Financial Income and Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "gmab:DisclosureOfFinanceIncomeExpensesTableTextBlock", "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw", "decimals": "-6", "first": true, "lang": null, "name": "gmab:InterestAndOtherFinancialIncome", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_IfrsRestrictedStockUnitsRSUsMember_4-5BFoS8HkmkHqZSV1-skg", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EquityInstruments_bRFAkAsdz0ugOZctjovS4A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - Share-Based Instruments - Restricted Stock Unit Program (Details)", "role": "http://www.genmab.com/role/DisclosureShareBasedInstrumentsRestrictedStockUnitProgramDetails", "shortName": "Share-Based Instruments - Restricted Stock Unit Program (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_IfrsRestrictedStockUnitsRSUsMember_4-5BFoS8HkmkHqZSV1-skg", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EquityInstruments_bRFAkAsdz0ugOZctjovS4A", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw", "decimals": "-6", "first": true, "lang": null, "name": "ifrs-full:ProceedsFromExerciseOfWarrants", "reportCount": 1, "unitRef": "Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40502 - Disclosure - Share-Based Instruments - Warrant Program (Details)", "role": "http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails", "shortName": "Share-Based Instruments - Warrant Program (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw", "decimals": "-6", "lang": null, "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw", "decimals": "INF", "first": true, "lang": null, "name": "gmab:ShareBasedArrangementNumberOfAuthorization", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_d-Yn30W8q0CdLFqZ4zWe8g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40503 - Disclosure - Share-Based Instruments - Share repurchases (Details)", "role": "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails", "shortName": "Share-Based Instruments - Share repurchases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw", "decimals": "INF", "first": true, "lang": null, "name": "gmab:ShareBasedArrangementNumberOfAuthorization", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_d-Yn30W8q0CdLFqZ4zWe8g", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw", "decimals": "INF", "first": true, "lang": null, "name": "gmab:NumberOfChangesToExecutiveManagementTeam", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_d-Yn30W8q0CdLFqZ4zWe8g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - Related Parties (Details)", "role": "http://www.genmab.com/role/DisclosureRelatedPartiesDetails", "shortName": "Related Parties (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw", "decimals": "INF", "first": true, "lang": null, "name": "gmab:NumberOfChangesToExecutiveManagementTeam", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_d-Yn30W8q0CdLFqZ4zWe8g", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg", "decimals": "-6", "first": true, "lang": null, "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - BALANCE SHEETS", "role": "http://www.genmab.com/role/StatementBalanceSheets", "shortName": "BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg", "decimals": "-6", "first": true, "lang": null, "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg", "decimals": "-6", "first": true, "lang": null, "name": "ifrs-full:RightofuseAssets", "reportCount": 1, "unitRef": "Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - Leases (Details)", "role": "http://www.genmab.com/role/DisclosureLeasesDetails", "shortName": "Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "gmab:DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "As_Of_6_30_2021_eEXLsHGqbE20an7xlGLjnw", "decimals": "-6", "lang": null, "name": "ifrs-full:RightofuseAssets", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw", "decimals": "-6", "first": true, "lang": null, "name": "ifrs-full:ProfitLossBeforeTax", "reportCount": 1, "unitRef": "Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - STATEMENTS OF CASH FLOWS", "role": "http://www.genmab.com/role/StatementStatementsOfCashFlows", "shortName": "STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw", "decimals": "-6", "lang": null, "name": "gmab:ReversalOfFinancialItemsNet", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_qxcDthXBpku77YP5whaVYg", "decimals": "-6", "first": true, "lang": null, "name": "ifrs-full:Equity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - STATEMENTS OF CHANGES IN EQUITY", "role": "http://www.genmab.com/role/StatementStatementsOfChangesInEquity", "shortName": "STATEMENTS OF CHANGES IN EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_qxcDthXBpku77YP5whaVYg", "decimals": "-6", "first": true, "lang": null, "name": "ifrs-full:Equity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - Basis of Presentation", "role": "http://www.genmab.com/role/DisclosureBasisOfPresentation", "shortName": "Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - Revenue", "role": "http://www.genmab.com/role/DisclosureRevenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - Financial Instruments", "role": "http://www.genmab.com/role/DisclosureFinancialInstruments", "shortName": "Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - Financial Income and Expenses", "role": "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpenses", "shortName": "Financial Income and Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "gmab-20220630xex99d1.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 47, "tag": { "country_DK": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DENMARK" } } }, "localname": "DK", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.genmab.com/role/DisclosureLeasesDetails" ], "xbrltype": "domainItemType" }, "currency_AllCurrenciesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "All Currencies [Domain]" } } }, "localname": "AllCurrenciesDomain", "nsuri": "http://xbrl.sec.gov/currency/2021", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails" ], "xbrltype": "domainItemType" }, "currency_DKK": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DKK" } } }, "localname": "DKK", "nsuri": "http://xbrl.sec.gov/currency/2021", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails" ], "xbrltype": "domainItemType" }, "currency_EUR": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Euro Member Countries, Euro" } } }, "localname": "EUR", "nsuri": "http://xbrl.sec.gov/currency/2021", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails" ], "xbrltype": "domainItemType" }, "currency_GBP": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "United Kingdom, Pounds" } } }, "localname": "GBP", "nsuri": "http://xbrl.sec.gov/currency/2021", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails" ], "xbrltype": "domainItemType" }, "currency_USD": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "United States of America, Dollars" } } }, "localname": "USD", "nsuri": "http://xbrl.sec.gov/currency/2021", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.genmab.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.genmab.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r184", "r185", "r186" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.genmab.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.genmab.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.genmab.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.genmab.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.genmab.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.genmab.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r182" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.genmab.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r185" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.genmab.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.genmab.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.genmab.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r183" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.genmab.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.genmab.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.genmab.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r183" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.genmab.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r190" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.genmab.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r183" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.genmab.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r188" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.genmab.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r183" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.genmab.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r183" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.genmab.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.genmab.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r189" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.genmab.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "gmab_AdjustmentsForInterestOnLeasePayments": { "auth_ref": [], "calculation": { "http://www.genmab.com/role/StatementStatementsOfCashFlows": { "order": 4.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments for interest on lease payments to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments For Interest On Lease Payments", "terseLabel": "Interest elements of lease payments" } } }, "localname": "AdjustmentsForInterestOnLeasePayments", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "gmab_AgreementsWithAbbvieMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for collaboration arrangement with Abbvie.", "label": "AbbVie" } } }, "localname": "AgreementsWithAbbvieMember", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails", "http://www.genmab.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "gmab_AgreementsWithBointechMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for collaboration arrangements with BioNTech.", "label": "BioNTech" } } }, "localname": "AgreementsWithBointechMember", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "gmab_AgreementsWithJanssenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for collaborative arrangement with Janssen (Darzalex/Daratumumab & DuoBody).", "label": "Janssen" } } }, "localname": "AgreementsWithJanssenMember", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "gmab_AgreementsWithNovartisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for collaborative arrangement with Novartis (Arzaerra/Ofatumumab).", "label": "Novartis (Arzaerra/Ofatumumab)" } } }, "localname": "AgreementsWithNovartisMember", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "gmab_AgreementsWithRocheMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for collaboration arrangement with Roche.", "label": "Roche" } } }, "localname": "AgreementsWithRocheMember", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "gmab_AgreementsWithSeagenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for collaboration arrangement with Seagen.", "label": "Seagen" } } }, "localname": "AgreementsWithSeagenMember", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "gmab_AgreementsWithSeatleGeneticsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for collaboration arrangement with Seatle Genetics", "label": "Seattle Genetics" } } }, "localname": "AgreementsWithSeatleGeneticsMember", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "gmab_AmericanDepositorySharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for American Depository Shares.", "label": "ADS" } } }, "localname": "AmericanDepositorySharesMember", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "gmab_BankDepositsIncludingShortTermMarketableSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of bank deposits including short-term marketable securities.", "label": "Bank Deposits Including Short Term Marketable Securities", "terseLabel": "Total value of bank deposits" } } }, "localname": "BankDepositsIncludingShortTermMarketableSecurities", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails" ], "xbrltype": "monetaryItemType" }, "gmab_BasisOfPresentationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Basis of Presentation" } } }, "localname": "BasisOfPresentationAbstract", "nsuri": "http://www.genmab.com/20220630", "xbrltype": "stringItemType" }, "gmab_BoltBiotherapeuticsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Bolt Biotherapeutics, Inc.", "label": "Bolt" } } }, "localname": "BoltBiotherapeuticsIncMember", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsOtherInvestmentsDetails" ], "xbrltype": "domainItemType" }, "gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems": { "auth_ref": [], "calculation": { "http://www.genmab.com/role/StatementStatementsOfCashFlows": { "order": 5.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities before reconciling the financial items.", "label": "Cash Flow From (Used In) Operating Activities Before Financial Items", "totalLabel": "Cash flows from operating activities before financial items" } } }, "localname": "CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "gmab_CollaborationRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for collaboration revenue.", "label": "Collaboration revenue" } } }, "localname": "CollaborationRevenueMember", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "gmab_CollaborativeAgreementProfitSharingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Profit sharing percentage under the collaboration agreement.", "label": "Collaborative Agreement, Profit Sharing Percentage", "terseLabel": "Profit sharing percentage under the collaboration agreement" } } }, "localname": "CollaborativeAgreementProfitSharingPercentage", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureBasisOfPresentationDetails" ], "xbrltype": "percentItemType" }, "gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaboration Agreements" } } }, "localname": "CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsOtherInvestmentsDetails" ], "xbrltype": "stringItemType" }, "gmab_CorporateTaxReceivable": { "auth_ref": [], "calculation": { "http://www.genmab.com/role/StatementBalanceSheets": { "order": 4.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Corporate Tax Receivable", "label": "Corporate Tax Receivable", "terseLabel": "Corporate tax receivable" } } }, "localname": "CorporateTaxReceivable", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "gmab_CurevacCollaborationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represent the information pertaining to CureVac Collaboration.", "label": "CureVac" } } }, "localname": "CurevacCollaborationMember", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsOtherInvestmentsDetails" ], "xbrltype": "domainItemType" }, "gmab_DarzalexMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for DARZALEX.", "label": "DARZALEX [Member]", "terseLabel": "DARZALEX" } } }, "localname": "DarzalexMember", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "gmab_DeirdreP.ConnellyChairPernilleErenbjergDeputyChairRolfHoffmannDr.PaoloPaolettiAndDr.AndersGerselPedersenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Deirdre P. Connelly (Chair), Pernille Erenbjerg (Deputy Chair), Rolf Hoffmann, Dr. Paolo Paoletti, and Dr. Anders Gersel Pedersen.", "label": "Deirdre P. Connelly (Chair), Pernille Erenbjerg (Deputy Chair), Rolf Hoffmann, Dr. Paolo Paoletti, and Dr. Anders Gersel Pedersen [Member]", "terseLabel": "Deirdre P. Connelly (Chair), Pernille Erenbjerg (Deputy Chair), Rolf Hoffmann, Dr. Paolo Paoletti, and Dr. Anders Gersel Pedersen" } } }, "localname": "DeirdreP.ConnellyChairPernilleErenbjergDeputyChairRolfHoffmannDr.PaoloPaolettiAndDr.AndersGerselPedersenMember", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "gmab_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The description of the entity's accounting policy for Basis of presentation.", "label": "Description Of Accounting Policy For Basis Of Presentation Policy [Text Block]", "terseLabel": "Accounting Policies" } } }, "localname": "DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "gmab_DescriptionOfAccountingPolicyForJudgmentsAndEstimatesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The description of the entity's accounting policy for Basis of presentation.", "label": "Description Of Accounting Policy For Judgments And Estimates [Policy Text Block]", "terseLabel": "Management Judgments and Estimates under IFRS" } } }, "localname": "DescriptionOfAccountingPolicyForJudgmentsAndEstimatesPolicyTextBlock", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "gmab_DescriptionOfAccountingPolicyForRecentAccountingStandardsAdoptedPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The description of the entity's accounting policy for recently adopted new accounting standards.", "label": "New Accounting Standards - Recently Adopted", "terseLabel": "New Accounting Policies and Disclosures" } } }, "localname": "DescriptionOfAccountingPolicyForRecentAccountingStandardsAdoptedPolicyTextBlock", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "gmab_DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of balance sheet information relating to leases.", "label": "Summary of balance sheet amounts relating to leases" } } }, "localname": "DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "gmab_DisclosureOfComprehensiveInformationRelatingToLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of comprehensive information relating to leases.", "label": "Summary of statement of comprehensive income amounts relating to leases" } } }, "localname": "DisclosureOfComprehensiveInformationRelatingToLeasesTableTextBlock", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "gmab_DisclosureOfCorporateAndDeferredTaxTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for corporate and deferred Tax.", "label": "Disclosure Of Corporate And Deferred Tax [Table Text Block]", "terseLabel": "Schedule of corporate and deferred Tax" } } }, "localname": "DisclosureOfCorporateAndDeferredTaxTableTextBlock", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureRevenueTables" ], "xbrltype": "textBlockItemType" }, "gmab_DisclosureOfFairValueMeasurementOfAssetsLevel3ReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of level 3 reconciliation of assets measured at fair value.", "label": "Disclosure Of Fair Value Measurement Of Assets, Level 3 Reconciliation [Table Text Block]", "terseLabel": "Schedule of level 3 reconciliation of assets" } } }, "localname": "DisclosureOfFairValueMeasurementOfAssetsLevel3ReconciliationTableTextBlock", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "gmab_DisclosureOfFinanceIncomeExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NA", "label": "Financial Income and Expenses" } } }, "localname": "DisclosureOfFinanceIncomeExpensesAbstract", "nsuri": "http://www.genmab.com/20220630", "xbrltype": "stringItemType" }, "gmab_DisclosureOfFinanceIncomeExpensesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "na", "label": "Schedule of financial income and expenses" } } }, "localname": "DisclosureOfFinanceIncomeExpensesTableTextBlock", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesTables" ], "xbrltype": "textBlockItemType" }, "gmab_DisclosureOfImpactOfExchangeRateOnNetResultBeforeTaxTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of impact of exchange rate on our net result before tax.", "label": "Disclosure Of Impact Of Exchange Rate On Net Result Before Tax [Table Text Block]", "terseLabel": "Schedule of impact of exchange rate on our net result before tax" } } }, "localname": "DisclosureOfImpactOfExchangeRateOnNetResultBeforeTaxTableTextBlock", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "gmab_DisclosureOfMarketableSecuritiesByCurrencyTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of marketable securities in foreign currency.", "label": "Disclosure Of Marketable Securities By Currency [Table Text Block]", "terseLabel": "Schedule of total marketable securities by currency" } } }, "localname": "DisclosureOfMarketableSecuritiesByCurrencyTableTextBlock", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "gmab_DisclosureOfMaturityProfileOfOurMarketableSecuritiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity profile of our marketable securities.", "label": "Disclosure Of Maturity Profile Of Our Marketable Securities [Table Text Block]", "terseLabel": "Schedule of maturity profile of our marketable securities" } } }, "localname": "DisclosureOfMaturityProfileOfOurMarketableSecuritiesTableTextBlock", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "gmab_DisclosureOfNetResultTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of net result for the year.", "label": "Disclosure Of Net Result [Table Text Block]", "terseLabel": "Schedule of net result" } } }, "localname": "DisclosureOfNetResultTableTextBlock", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureRevenueTables" ], "xbrltype": "textBlockItemType" }, "gmab_DisclosureOfNewAccountingPoliciesAndDisclosuresPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for new accounting policy and disclosures.", "label": "Disclosure Of New Accounting policies And Disclosures [Policy Text Block]", "terseLabel": "New Accounting Policies and Disclosures" } } }, "localname": "DisclosureOfNewAccountingPoliciesAndDisclosuresPolicyTextBlock", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "gmab_DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of warrants.", "label": "Disclosure Of Number And Weighted Average Exercise Prices Of Warrants [Table Text Block]", "terseLabel": "Schedule of Weighted Average Exercise Prices Of Warrants" } } }, "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsTableTextBlock", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "gmab_DisclosureOfStaffCostTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of staff cost.", "label": "Disclosure Of Staff Cost [Table Text Block]", "terseLabel": "Schedule of staff cost" } } }, "localname": "DisclosureOfStaffCostTableTextBlock", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureRevenueTables" ], "xbrltype": "textBlockItemType" }, "gmab_DisclosureOfWarrantsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants activity.", "label": "Disclosure Of Warrants Activity [Table Text Block]", "terseLabel": "Summary of warrants activity" } } }, "localname": "DisclosureOfWarrantsActivityTableTextBlock", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "gmab_DocumentAndEntityInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Document and Entity Information [Abstract]" } } }, "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.genmab.com/20220630", "xbrltype": "stringItemType" }, "gmab_ElectionToBoardOfDirectorsTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The term limit of board of directors.", "label": "Election to the Board of Directors, Term", "terseLabel": "Board of directors term" } } }, "localname": "ElectionToBoardOfDirectorsTerm", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureRelatedPartiesDetails" ], "xbrltype": "durationItemType" }, "gmab_ElizabethOfarrellMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Elizabeth O'Farrell.", "label": "Elizabeth O’Farrell [Member]", "terseLabel": "Elizabeth O'Farrell" } } }, "localname": "ElizabethOfarrellMember", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "gmab_EquityAdjustedForCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholder's equity, after the cumulative effect adjustment of a new accounting principle applied in the period of adoption.", "label": "Equity Adjusted For Cumulative Effect Of New Accounting Principle In Period Of Adoption", "terseLabel": "Adjusted total equity at January 1, 2018" } } }, "localname": "EquityAdjustedForCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "gmab_EstimatedCapitalExpenditureForLease": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of estimated capital expenditure for lease.", "label": "Estimated Capital Expenditure for Lease", "terseLabel": "Estimated capital expenditure for lease" } } }, "localname": "EstimatedCapitalExpenditureForLease", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureLeasesDetails" ], "xbrltype": "monetaryItemType" }, "gmab_ExerciseOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of warrants exercised.", "label": "Exercise of Warrants", "terseLabel": "Exercise of warrants (in shares)" } } }, "localname": "ExerciseOfWarrants", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfChangesInEquity" ], "xbrltype": "sharesItemType" }, "gmab_ExpensesRelatedToCapitalIncreaseDecrease": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Expenses Related To Capital Increase Decrease", "label": "Expenses Related To Capital Increase Decrease", "terseLabel": "Expenses related to capital increases" } } }, "localname": "ExpensesRelatedToCapitalIncreaseDecrease", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "gmab_FinanceExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "na", "label": "Financial expenses:" } } }, "localname": "FinanceExpensesAbstract", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "xbrltype": "stringItemType" }, "gmab_FinanceIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "na", "label": "Financial Income:" } } }, "localname": "FinanceIncomeAbstract", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "xbrltype": "stringItemType" }, "gmab_FutureMinimumOperatingLeasePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of future minimum operating lease payments.", "label": "Future Minimum Operating Lease Payments", "terseLabel": "Total future minimum payments" } } }, "localname": "FutureMinimumOperatingLeasePayments", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureLeasesDetails" ], "xbrltype": "monetaryItemType" }, "gmab_GainOnOtherInvestments": { "auth_ref": [], "calculation": { "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "order": 3.0, "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gains on other investments.", "label": "Gain On Other Investments", "terseLabel": "Gain on other investments, net" } } }, "localname": "GainOnOtherInvestments", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "gmab_GainsOnHedgingInstruments": { "auth_ref": [], "calculation": { "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "order": 2.0, "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gains on hedging instruments in fair value hedges.", "label": "Realized and unrealized gains on fair value hedges, net", "terseLabel": "Realized and unrealized gains on fair value hedges, net" } } }, "localname": "GainsOnHedgingInstruments", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Ifrs Collaborative Arrangement and Arrangement Other Than Collaborative [Axis]" } } }, "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails", "http://www.genmab.com/role/DisclosureFinancialInstrumentsOtherInvestmentsDetails", "http://www.genmab.com/role/DisclosureRevenueDetails" ], "xbrltype": "stringItemType" }, "gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Ifrs Collaborative Arrangement and Arrangement Other Than Collaborative [Domain]" } } }, "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails", "http://www.genmab.com/role/DisclosureFinancialInstrumentsOtherInvestmentsDetails", "http://www.genmab.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Ifrs Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsOtherInvestmentsDetails" ], "xbrltype": "stringItemType" }, "gmab_IfrsCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.", "label": "Ifrs Cumulative Effect of New Accounting Principle in Period of Adoption", "terseLabel": "Change in accounting policy: Adoption of IFRS 15" } } }, "localname": "IfrsCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "gmab_IfrsEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to equipment.", "label": "Equipment" } } }, "localname": "IfrsEquipmentMember", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureLeasesDetails" ], "xbrltype": "domainItemType" }, "gmab_IfrsMarketableSecuritiesCurrent": { "auth_ref": [], "calculation": { "http://www.genmab.com/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments in debt and equity securities which have original maturities over to 90 days, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.", "label": "Ifrs Marketable Securities Current", "terseLabel": "Marketable securities" } } }, "localname": "IfrsMarketableSecuritiesCurrent", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "gmab_IfrsNumberOfReportingUnits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.", "label": "Number of business unit" } } }, "localname": "IfrsNumberOfReportingUnits", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureBasisOfPresentationDetails" ], "xbrltype": "integerItemType" }, "gmab_IfrsRestrictedStockUnitsRSUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "RSUs" } } }, "localname": "IfrsRestrictedStockUnitsRSUsMember", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsRestrictedStockUnitProgramDetails" ], "xbrltype": "domainItemType" }, "gmab_IfrsRoyaltiesByProductAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by royalties by product.", "label": "ifrs Royalties by Product [Axis]" } } }, "localname": "IfrsRoyaltiesByProductAxis", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureRevenueDetails" ], "xbrltype": "stringItemType" }, "gmab_IfrsRoyaltiesByProductDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by royalties by product.", "label": "ifrs Royalties by Product [Domain]" } } }, "localname": "IfrsRoyaltiesByProductDomain", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "gmab_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period which the right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "IFRS Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails" ], "xbrltype": "durationItemType" }, "gmab_IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in equity resulting from net settlement of restricted stock units.", "label": "Increase Decrease Through Net Settlement Of Restricted Stock Units, Equity", "terseLabel": "Net settlement of RSUs" } } }, "localname": "IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "gmab_IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in equity resulting from tax on items recognized directly in equity.", "label": "Increase Decrease Through Tax On Items Recognized Directly In Equity", "terseLabel": "Tax on items recognized directly in equity" } } }, "localname": "IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "gmab_InterestAndOtherFinancialExpenses": { "auth_ref": [], "calculation": { "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "order": 3.0, "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The interest and other financial expenses.", "label": "Interest and Other Financial Expenses", "negatedLabel": "Interest and other financial expenses" } } }, "localname": "InterestAndOtherFinancialExpenses", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "gmab_InterestAndOtherFinancialIncome": { "auth_ref": [], "calculation": { "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "order": 4.0, "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The interest and other financial income.", "label": "Interest and Other Financial Income", "terseLabel": "Interest and other financial income" } } }, "localname": "InterestAndOtherFinancialIncome", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "gmab_KesimptaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Kesimpta.", "label": "Kesimpta [Member]", "terseLabel": "Kesimpta" } } }, "localname": "KesimptaMember", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "gmab_LicenseFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for revenue from license fees.", "label": "License fees" } } }, "localname": "LicenseFeesMember", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "gmab_LossesOnMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "order": 2.0, "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The losses on marketable securities.", "label": "Losses on Marketable Securities", "negatedLabel": "Loss on marketable securities, net" } } }, "localname": "LossesOnMarketableSecurities", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "gmab_LossesOnOtherInvestmentsNet": { "auth_ref": [], "calculation": { "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "order": 4.0, "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Losses On Other Investments Net", "label": "Losses On Other Investments Net", "negatedLabel": "Loss on other investments, net" } } }, "localname": "LossesOnOtherInvestmentsNet", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "gmab_MarketableSecuritiesIncludingInterestReceivables": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of marketable securities including interest receivable.", "label": "Marketable Securities Including Interest Receivables", "terseLabel": "Marketable securities including interest receivables" } } }, "localname": "MarketableSecuritiesIncludingInterestReceivables", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails" ], "xbrltype": "monetaryItemType" }, "gmab_MarketableSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for marketable securities .", "label": "Marketable Securities" } } }, "localname": "MarketableSecuritiesMember", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "gmab_MijkeZachariasseMartinSchultzAndTakahiroHamataniMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Mijke Zachariasse, Martin Schultz and Takahiro Hamatani.", "label": "Mijke Zachariasse, Martin Schultz and Takahiro Hamatani [Member]", "terseLabel": "Mijke Zachariasse, Martin Schultz and Takahiro Hamatani" } } }, "localname": "MijkeZachariasseMartinSchultzAndTakahiroHamataniMember", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "gmab_MilestonePaymentsRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for revenue from milestone payments.", "label": "Milestone payments" } } }, "localname": "MilestonePaymentsRevenueMember", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "gmab_NumberOfApprovedProductsCommercializedByThirdParties": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of approved products commercialized by third parties.", "label": "Number Of Approved Products Commercialized By Third Parties", "terseLabel": "Number of approved products commercialized by third parties" } } }, "localname": "NumberOfApprovedProductsCommercializedByThirdParties", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureBasisOfPresentationDetails" ], "xbrltype": "integerItemType" }, "gmab_NumberOfApprovedProductsJointlyCommercializedWithCollaboration": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of approved products jointly commercialized by collaboration partner.", "label": "Number Of Approved Products Jointly Commercialized With Collaboration", "terseLabel": "Number of approved products jointly commercialized by collaboration partner" } } }, "localname": "NumberOfApprovedProductsJointlyCommercializedWithCollaboration", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureBasisOfPresentationDetails" ], "xbrltype": "integerItemType" }, "gmab_NumberOfChangesToExecutiveManagementTeam": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of changes to executive management team.", "label": "Number of Changes to Executive Management Team", "terseLabel": "Number of changes to executive management team" } } }, "localname": "NumberOfChangesToExecutiveManagementTeam", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureRelatedPartiesDetails" ], "xbrltype": "integerItemType" }, "gmab_NumberOfEmployeeElectedBoardMembers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of employee elected board members.", "label": "Number of Employee Elected Board Members", "terseLabel": "Number of employee elected board members" } } }, "localname": "NumberOfEmployeeElectedBoardMembers", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureRelatedPartiesDetails" ], "xbrltype": "integerItemType" }, "gmab_NumberOfIndependentBoardMembers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of independent board members.", "label": "Number of Independent Board Members", "terseLabel": "Number of independent board members" } } }, "localname": "NumberOfIndependentBoardMembers", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureRelatedPartiesDetails" ], "xbrltype": "integerItemType" }, "gmab_NumberOfNonIndependentBoardMembers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non independent board members.", "label": "Number of Non Independent Board Members", "terseLabel": "Number of non independent board members" } } }, "localname": "NumberOfNonIndependentBoardMembers", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureRelatedPartiesDetails" ], "xbrltype": "integerItemType" }, "gmab_NumberOfSharesAuthorizedToBeRepurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.", "label": "Number Of Shares Authorized To Be Repurchased", "terseLabel": "Number of shares authorized for repurchase" } } }, "localname": "NumberOfSharesAuthorizedToBeRepurchased", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails" ], "xbrltype": "sharesItemType" }, "gmab_NumberOfTreasurySharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares that has been held in treasury.", "label": "Number of Treasury Shares Outstanding", "terseLabel": "Treasury shares outstanding" } } }, "localname": "NumberOfTreasurySharesOutstanding", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails" ], "xbrltype": "sharesItemType" }, "gmab_NumberOfWarrantsExercisedDuringPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of warrants exercised during period.", "label": "Number Of Warrants Exercised During Period", "terseLabel": "Exercised" } } }, "localname": "NumberOfWarrantsExercisedDuringPeriod", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails" ], "xbrltype": "sharesItemType" }, "gmab_NumberOfWarrantsExpiredOrLapsedOrCancelledDuringPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of warrants expired or lapsed or cancelled during period.", "label": "Number Of Warrants Expired Or Lapsed Or Cancelled During Period", "negatedLabel": "Expired/lapsed/cancelled" } } }, "localname": "NumberOfWarrantsExpiredOrLapsedOrCancelledDuringPeriod", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails" ], "xbrltype": "sharesItemType" }, "gmab_NumberOfWarrantsGrantedDuringPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of warrants granted during period.", "label": "Number Of Warrants Granted During Period", "terseLabel": "Granted" } } }, "localname": "NumberOfWarrantsGrantedDuringPeriod", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails" ], "xbrltype": "sharesItemType" }, "gmab_NumberOfWarrantsOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of warrants held as of the balance sheet date.", "label": "Number Of Warrants Outstanding", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period" } } }, "localname": "NumberOfWarrantsOutstanding", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails" ], "xbrltype": "sharesItemType" }, "gmab_OfficeAndLaboratorySpaceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Office and laboratory space.", "label": "Office and laboratory space" } } }, "localname": "OfficeAndLaboratorySpaceMember", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureLeasesDetails" ], "xbrltype": "domainItemType" }, "gmab_OtherCollaborationPartnersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for collaborative arrangement with other collaboration partners.", "label": "Other collaboration partners" } } }, "localname": "OtherCollaborationPartnersMember", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "gmab_OtherInvestmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to other investments.", "label": "Other" } } }, "localname": "OtherInvestmentMember", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "gmab_OtherRoyaltyProductMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for other royalty product.", "label": "Other Royalty Product [Member]", "terseLabel": "Other Royalty Product" } } }, "localname": "OtherRoyaltyProductMember", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "gmab_PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs": { "auth_ref": [], "calculation": { "http://www.genmab.com/role/StatementStatementsOfCashFlows": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for withholding taxes on behalf of employees on net settled restricted stock units (RSUs).", "label": "Payment Of Withholding Taxes On Behalf Of Employees On Net Settled R S Us", "negatedLabel": "Payment of withholding taxes on behalf of employees on net settled RSUs" } } }, "localname": "PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "gmab_PaymentsToAcquireTreasuryShares": { "auth_ref": [], "calculation": { "http://www.genmab.com/role/StatementStatementsOfCashFlows": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire treasury shares.", "label": "Payments To Acquire Treasury Shares", "negatedLabel": "Purchase of treasury shares" } } }, "localname": "PaymentsToAcquireTreasuryShares", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "gmab_PercentageOfInvestmentInCommonShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of investment in common shares.", "label": "Percentage of Investment in Common Shares", "terseLabel": "Percentage of investment in common shares" } } }, "localname": "PercentageOfInvestmentInCommonShares", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsOtherInvestmentsDetails" ], "xbrltype": "percentItemType" }, "gmab_PercentageOfMarketableSecurities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of marketable securities.", "label": "Percentage of Marketable Securities", "terseLabel": "Percentage of marketable securities" } } }, "localname": "PercentageOfMarketableSecurities", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails" ], "xbrltype": "percentItemType" }, "gmab_PercentageOfMarketableSecuritiesInvested": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of marketable securities invested.", "label": "Percentage of Marketable Securities Invested", "terseLabel": "Marketable securities were invested (as a percent)" } } }, "localname": "PercentageOfMarketableSecuritiesInvested", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails" ], "xbrltype": "percentItemType" }, "gmab_PercentageOfPossibleIncreaseDecreaseInExchangeRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of possible increase or decrease in exchange rate.", "label": "Percentage Of Possible Increase (Decrease) In Exchange rate", "terseLabel": "Percentage of possible increase or decrease in exchange rate" } } }, "localname": "PercentageOfPossibleIncreaseDecreaseInExchangeRate", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails" ], "xbrltype": "percentItemType" }, "gmab_PercentageOfRevenue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of revenue.", "label": "Percentage of Revenue", "terseLabel": "Revenue (as a percent)" } } }, "localname": "PercentageOfRevenue", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails" ], "xbrltype": "percentItemType" }, "gmab_PercentageOfShareCapitalAttributedToExerciseOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of share capital attributed by exercise of warrants which increase the share capital.", "label": "Percentage Of Share Capital Attributed To Exercise Of Warrants", "terseLabel": "Percentage of share capital attributed to exercise of warrants" } } }, "localname": "PercentageOfShareCapitalAttributedToExerciseOfWarrants", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails" ], "xbrltype": "percentItemType" }, "gmab_PercentageOfShareCapitalRepurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of share capital repurchased.", "label": "Percentage Of Share Capital Repurchased", "terseLabel": "Percentage of share capital repurchased" } } }, "localname": "PercentageOfShareCapitalRepurchased", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails" ], "xbrltype": "percentItemType" }, "gmab_PropertiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to properties.", "label": "Properties" } } }, "localname": "PropertiesMember", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureLeasesDetails" ], "xbrltype": "domainItemType" }, "gmab_ReElectionToBoardOfDirectorsTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The term limit of board of directors who are re-elected.", "label": "Re-Election to the Board of Directors Term", "terseLabel": "Re-election to the board of directors term" } } }, "localname": "ReElectionToBoardOfDirectorsTerm", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureRelatedPartiesDetails" ], "xbrltype": "durationItemType" }, "gmab_ReimbursementIncomeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for reimbursement income.", "label": "Reimbursement income" } } }, "localname": "ReimbursementIncomeMember", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "gmab_RestrictedStockUnitsRSUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "RSU" } } }, "localname": "RestrictedStockUnitsRSUsMember", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails" ], "xbrltype": "domainItemType" }, "gmab_ReversalOfFinancialItemsNet": { "auth_ref": [], "calculation": { "http://www.genmab.com/role/StatementStatementsOfCashFlows": { "order": 3.0, "parentTag": "gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The reversal of financial items to the cash flow under operating activities.", "label": "Reversal Of Financial Items, Net", "negatedLabel": "Reversal of financial items, net" } } }, "localname": "ReversalOfFinancialItemsNet", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "gmab_RoyaltiesRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for revenue form royalties.", "label": "Royalties" } } }, "localname": "RoyaltiesRevenueMember", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "gmab_ScheduleOfPortfolioOfMarketableSecurities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of portfolio of marketable securities.", "label": "Schedule Of Portfolio Of Marketable Securities", "terseLabel": "Schedule of portfolio of marketable securities" } } }, "localname": "ScheduleOfPortfolioOfMarketableSecurities", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "gmab_ScheduleOfSegmentDisclosuresInFinancialStatementsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for segment disclosures in the financial statements as the group's business activities.", "label": "Schedule Of Segment Disclosures In Financial Statements [Table Text Block]", "terseLabel": "Schedule of segment disclosures in the financial statements as the group's business activities." } } }, "localname": "ScheduleOfSegmentDisclosuresInFinancialStatementsTableTextBlock", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureRevenueTables" ], "xbrltype": "textBlockItemType" }, "gmab_ScheduleOfShareRepurchasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of repurchase of shares.", "label": "Schedule of Share Repurchases [Table Text Block]", "terseLabel": "Schedule of share repurchases" } } }, "localname": "ScheduleOfShareRepurchasesTableTextBlock", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "gmab_ShareBasedArrangementNumberOfAuthorization": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of authorization under the share based payment arrangements.", "label": "Share Based Arrangement, Number Of Authorization", "terseLabel": "Number of authorization" } } }, "localname": "ShareBasedArrangementNumberOfAuthorization", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails" ], "xbrltype": "integerItemType" }, "gmab_ShareBasedArrangementNumberOfSharesPerRsu": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares credited for one share of RSU owned by the holder under the share based payment arrangements.", "label": "Share Based Arrangement, Number Of Shares Per RSU", "terseLabel": "Number of shares per RSU" } } }, "localname": "ShareBasedArrangementNumberOfSharesPerRsu", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails" ], "xbrltype": "sharesItemType" }, "gmab_ShareBasedArrangementPeriodFromVestingDateHolderReceivesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period from vesting date in which the holder receives shares in the account per RSU under the share based payments arrangement.", "label": "Share Based Arrangement, Period From Vesting Date The Holder Receives Shares", "terseLabel": "Period from vesting date for crediting shares" } } }, "localname": "ShareBasedArrangementPeriodFromVestingDateHolderReceivesShares", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails" ], "xbrltype": "durationItemType" }, "gmab_ShareRepurchasedDuringPeriodShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury.", "label": "Share Repurchased During Period Shares", "terseLabel": "Actual shares repurchased under authorization" } } }, "localname": "ShareRepurchasedDuringPeriodShares", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails" ], "xbrltype": "sharesItemType" }, "gmab_ShareRepurchasedDuringPeriodValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of stock that has been repurchased during the period and has not been retired and is not held in treasury.", "label": "Share Repurchased During Period Value", "terseLabel": "Share repurchased amount" } } }, "localname": "ShareRepurchasedDuringPeriodValue", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails" ], "xbrltype": "monetaryItemType" }, "gmab_SharesAvailableForRepurchase": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares available for repurchase.", "label": "Shares Available For Repurchase", "terseLabel": "Shares available for repurchase" } } }, "localname": "SharesAvailableForRepurchase", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails" ], "xbrltype": "sharesItemType" }, "gmab_SharesAvailableForRepurchaseAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of shares that are available for repurchase.", "label": "Shares Available For Repurchase Amount", "terseLabel": "Shares available for repurchase amount" } } }, "localname": "SharesAvailableForRepurchaseAmount", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails" ], "xbrltype": "monetaryItemType" }, "gmab_SharesRepurchasedNominalValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Nominal value of share repurchased.", "label": "Shares Repurchased Nominal Value", "terseLabel": "Nominal value of shares repurchases" } } }, "localname": "SharesRepurchasedNominalValue", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails" ], "xbrltype": "monetaryItemType" }, "gmab_StaffCostsIncludedInGeneralAndAdministrativeExpenses": { "auth_ref": [], "calculation": { "http://www.genmab.com/role/DisclosureResultsForYearStaffCostsDetailsCalc2": { "order": 2.0, "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of staff cost included in research and development expenses.", "label": "Staff Costs Included In General and administrative expenses" } } }, "localname": "StaffCostsIncludedInGeneralAndAdministrativeExpenses", "nsuri": "http://www.genmab.com/20220630", "xbrltype": "monetaryItemType" }, "gmab_StaffCostsIncludedInGovernmentGrantsRelatedToResearchAndDevelopmentExpenses": { "auth_ref": [], "calculation": { "http://www.genmab.com/role/DisclosureResultsForYearStaffCostsDetailsCalc2": { "order": 4.0, "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of staff cost included in government grants related to research and development expenses.", "label": "Staff Costs Included In Government Grants Related To Research And Development Expenses" } } }, "localname": "StaffCostsIncludedInGovernmentGrantsRelatedToResearchAndDevelopmentExpenses", "nsuri": "http://www.genmab.com/20220630", "xbrltype": "monetaryItemType" }, "gmab_StaffCostsIncludedInResearchAndDevelopmentExpense": { "auth_ref": [], "calculation": { "http://www.genmab.com/role/DisclosureResultsForYearStaffCostsDetailsCalc2": { "order": 1.0, "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of staff cost included in research and development expenses.", "label": "Staff Costs Included In Research And Development Expense" } } }, "localname": "StaffCostsIncludedInResearchAndDevelopmentExpense", "nsuri": "http://www.genmab.com/20220630", "xbrltype": "monetaryItemType" }, "gmab_StaffCostsIncludedInSellingGeneralAndAdministrativeExpenses": { "auth_ref": [], "calculation": { "http://www.genmab.com/role/DisclosureResultsForYearStaffCostsDetailsCalc2": { "order": 3.0, "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of staff cost included in selling, general and administrative expenses.", "label": "Staff Costs Included in Selling, General and Administrative Expenses" } } }, "localname": "StaffCostsIncludedInSellingGeneralAndAdministrativeExpenses", "nsuri": "http://www.genmab.com/20220630", "xbrltype": "monetaryItemType" }, "gmab_StockRepurchaseAuthorization2016Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the 2016 authorization under the share repurchase arrangement by the board of directors.", "label": "Stock Repurchase Authorization 2016 [Member]", "terseLabel": "2016 Authorization" } } }, "localname": "StockRepurchaseAuthorization2016Member", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails" ], "xbrltype": "domainItemType" }, "gmab_StockRepurchaseAuthorization2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the 2019 authorization under the share repurchase arrangement by the board of directors.", "label": "Stock Repurchase Authorization 2019 [Member]", "terseLabel": "2019 Authorization" } } }, "localname": "StockRepurchaseAuthorization2019Member", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails" ], "xbrltype": "domainItemType" }, "gmab_StockRepurchaseAuthorization2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the 2021 authorization under the share repurchase arrangement by the board of directors.", "label": "Stock Repurchase Authorization 2021 [Member]", "terseLabel": "2021 Authorization" } } }, "localname": "StockRepurchaseAuthorization2021Member", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails" ], "xbrltype": "domainItemType" }, "gmab_StockRepurchaseFirstAuthorizationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the first authorization under the share repurchase arrangement by the board of directors.", "label": "First authorization" } } }, "localname": "StockRepurchaseFirstAuthorizationMember", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails" ], "xbrltype": "domainItemType" }, "gmab_StockRepurchaseSecondAuthorizationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the second authorization under the share repurchase arrangement by the board of directors.", "label": "Second authorization" } } }, "localname": "StockRepurchaseSecondAuthorizationMember", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails" ], "xbrltype": "domainItemType" }, "gmab_StockRepurchaseThresholdPriceDeviationPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the threshold price deviation percentage under stock repurchase arrangement.", "label": "Stock Repurchase Threshold Price Deviation Percentage", "terseLabel": "Threshold price deviation percentage" } } }, "localname": "StockRepurchaseThresholdPriceDeviationPercentage", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails" ], "xbrltype": "percentItemType" }, "gmab_TaxOnItemsRecognizedDirectlyInEquity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Tax on items recognized directly in equity.", "label": "Tax On Items Recognized Directly In Equity" } } }, "localname": "TaxOnItemsRecognizedDirectlyInEquity", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "gmab_TepezzaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for TEPEZZA.", "label": "TEPEZZA [Member]", "terseLabel": "TEPEZZA" } } }, "localname": "TepezzaMember", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "gmab_ThirdAuthorizationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the third authorization under the share repurchase arrangement by the board of directors.", "label": "Third Authorization [Member]", "terseLabel": "Third authorization" } } }, "localname": "ThirdAuthorizationMember", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails" ], "xbrltype": "domainItemType" }, "gmab_TotalAdjustmentsForNonCashTransactions": { "auth_ref": [], "calculation": { "http://www.genmab.com/role/StatementStatementsOfCashFlows": { "order": 2.0, "parentTag": "gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments for total non-cash items to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Total Adjustments For Non Cash Transactions", "terseLabel": "Adjustments for non-cash transactions" } } }, "localname": "TotalAdjustmentsForNonCashTransactions", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "gmab_TransactionsWithOwners": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "n/a", "label": "Transactions With Owners", "terseLabel": "Transactions with owners:" } } }, "localname": "TransactionsWithOwners", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfChangesInEquity" ], "xbrltype": "stringItemType" }, "gmab_TreasurySharesAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of treasury shares acquired during period.", "label": "Purchase of treasury shares.", "terseLabel": "Treasury shares acquired" } } }, "localname": "TreasurySharesAcquired", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails" ], "xbrltype": "sharesItemType" }, "gmab_TripleaRatingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Triple A-rating.", "label": "Triple A-rating from Moody's, S&P or Fitch" } } }, "localname": "TripleaRatingMember", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails" ], "xbrltype": "domainItemType" }, "gmab_TypesOfRevenuesAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Types of revenues [axis]" } } }, "localname": "TypesOfRevenuesAxis", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureRevenueDetails" ], "xbrltype": "stringItemType" }, "gmab_TypesOfRevenuesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for This member stands for all types of revenues from customers. It also represents the standard value for the 'Types of revenues' axis if no other member is used.", "label": "Types of revenues [member]" } } }, "localname": "TypesOfRevenuesMember", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "gmab_ValuationAssumptionsForWarrantsGrantedTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of fair value of each warrant granted.", "label": "Valuation Assumptions for Warrants Granted [Table Text Block]", "terseLabel": "Fair value of each warrant granted" } } }, "localname": "ValuationAssumptionsForWarrantsGrantedTableTextBlock", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureRevenueTables" ], "xbrltype": "textBlockItemType" }, "gmab_WarrantVestingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period which the right to exercise an warrant is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Warrant Vesting Period", "terseLabel": "Warrant vesting period" } } }, "localname": "WarrantVestingPeriod", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails" ], "xbrltype": "durationItemType" }, "gmab_WarrantsGrantedFromApril2012UntilMarch2017Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the warrants granted from April 2012 until March 2017.", "label": "Warrants Granted from April 2012 until March 2017" } } }, "localname": "WarrantsGrantedFromApril2012UntilMarch2017Member", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails" ], "xbrltype": "domainItemType" }, "gmab_WarrantsGrantedFromAugust2004UntilApril2012Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the warrants granted from August 2004 until April 2012.", "label": "Warrants Granted from August 2004 until April 2012" } } }, "localname": "WarrantsGrantedFromAugust2004UntilApril2012Member", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails" ], "xbrltype": "domainItemType" }, "gmab_WarrantsGrantedFromMarch2017Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the warrants granted from march 2017.", "label": "Warrants Granted from March 2017" } } }, "localname": "WarrantsGrantedFromMarch2017Member", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails" ], "xbrltype": "domainItemType" }, "gmab_WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants [Member]", "label": "Warrants [Member]" } } }, "localname": "WarrantsMember", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails" ], "xbrltype": "domainItemType" }, "gmab_WeightedAverageExercisePriceOfFairValueOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of fair value of warrants during the period.", "label": "Weighted Average Exercise Price Of Fair Value Of Warrants", "terseLabel": "Weighted average exercise price of fair market value" } } }, "localname": "WeightedAverageExercisePriceOfFairValueOfWarrants", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails" ], "xbrltype": "perShareItemType" }, "gmab_WeightedAverageExercisePriceOfWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants exercised during the period.", "label": "Weighted Average Exercise Price Of Warrants Exercised", "terseLabel": "Weighted average exercise price of warrants exercised" } } }, "localname": "WeightedAverageExercisePriceOfWarrantsExercised", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails" ], "xbrltype": "perShareItemType" }, "gmab_WeightedAverageExercisePriceOfWarrantsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants granted during the period.", "label": "Weighted Average Exercise Price Of Warrants Granted", "terseLabel": "Weighted average exercise price of warrants granted" } } }, "localname": "WeightedAverageExercisePriceOfWarrantsGranted", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails" ], "xbrltype": "perShareItemType" }, "gmab_Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value of other equity instruments (i.e. other than share options) granted in a share-based payment arrangement.", "label": "WeightedAverageFairValueOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement", "terseLabel": "Weighted average fair value of RSU granted" } } }, "localname": "Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement", "nsuri": "http://www.genmab.com/20220630", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsRestrictedStockUnitProgramDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_AdditionsToRightofuseAssets": { "auth_ref": [ "r121" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]" } }, "en-us": { "role": { "label": "Additions to right-of-use assets", "terseLabel": "Additions to right of use assets" } } }, "localname": "AdditionsToRightofuseAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureLeasesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForIncomeTaxExpense": { "auth_ref": [ "r86" ], "calculation": { "http://www.genmab.com/role/StatementStatementsOfCashFlows": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for income tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for income tax expense", "terseLabel": "Corporate taxes paid" } } }, "localname": "AdjustmentsForIncomeTaxExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AggregatedMeasurementMember": { "auth_ref": [ "r73", "r74", "r108" ], "lang": { "en": { "role": { "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used." } }, "en-us": { "role": { "label": "Aggregated measurement [member]" } } }, "localname": "AggregatedMeasurementMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AllLevelsOfFairValueHierarchyMember": { "auth_ref": [ "r55", "r109" ], "lang": { "en": { "role": { "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used." } }, "en-us": { "role": { "label": "All levels of fair value hierarchy [member]" } } }, "localname": "AllLevelsOfFairValueHierarchyMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Assets": { "auth_ref": [ "r24", "r108", "r109", "r110", "r156", "r160" ], "calculation": { "http://www.genmab.com/role/StatementBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } }, "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "ifrs-full_AtFairValueMember": { "auth_ref": [ "r73", "r74", "r108" ], "lang": { "en": { "role": { "documentation": "This member stands for measurement based on fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date." } }, "en-us": { "role": { "label": "Net Book value" } } }, "localname": "AtFairValueMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_BasicEarningsLossPerShare": { "auth_ref": [ "r64", "r65" ], "lang": { "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } }, "en-us": { "role": { "label": "Basic earnings (loss) per share", "terseLabel": "Basic net profit per share" } } }, "localname": "BasicEarningsLossPerShare", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome" ], "xbrltype": "perShareItemType" }, "ifrs-full_Cash": { "auth_ref": [ "r88" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]" } }, "en-us": { "role": { "label": "Cash", "terseLabel": "Bank deposits" } } }, "localname": "Cash", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashAndCashEquivalents": { "auth_ref": [ "r21", "r88", "r105" ], "calculation": { "http://www.genmab.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } }, "en-us": { "role": { "label": "Cash and cash equivalents", "periodEndLabel": "Cash and cash equivalents at the end of the period", "periodStartLabel": "Cash and cash equivalents at the beginning of the period", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementBalanceSheets", "http://www.genmab.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents [abstract]", "terseLabel": "Cash and cash equivalents include:" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowHedgesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flow hedges [abstract]", "terseLabel": "Fair value adjustments of cash flow hedges:" } } }, "localname": "CashFlowHedgesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowHedgesMember": { "auth_ref": [ "r72", "r132", "r133", "r135" ], "lang": { "en": { "role": { "documentation": "This member stands for hedges of the exposure to variability in cash flows that (a) are attributable to a particular risk associated with a recognised asset or liability (such as all or some future interest payments on variable rate debt) or a highly probable forecast transaction; and (b) could affect profit or loss. [Refer: Hedges [member]]" } }, "en-us": { "role": { "label": "Cash flow hedges [member]" } } }, "localname": "CashFlowHedgesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "auth_ref": [ "r75", "r89" ], "calculation": { "http://www.genmab.com/role/StatementStatementsOfCashFlows": { "order": 2.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity." } }, "en-us": { "role": { "label": "Cash flows from (used in) financing activities", "totalLabel": "Net cash (used in) financing activities" } } }, "localname": "CashFlowsFromUsedInFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) financing activities [abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "auth_ref": [ "r75", "r89" ], "calculation": { "http://www.genmab.com/role/StatementStatementsOfCashFlows": { "order": 3.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents." } }, "en-us": { "role": { "label": "Cash flows from (used in) investing activities", "totalLabel": "Net cash (used in) / provided by investing activities" } } }, "localname": "CashFlowsFromUsedInInvestingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) investing activities [abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "auth_ref": [ "r75", "r89" ], "calculation": { "http://www.genmab.com/role/StatementStatementsOfCashFlows": { "order": 1.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]" } }, "en-us": { "role": { "label": "Cash flows from (used in) operating activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "CashFlowsFromUsedInOperatingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operating activities [abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities": { "auth_ref": [ "r87" ], "calculation": { "http://www.genmab.com/role/StatementStatementsOfCashFlows": { "order": 7.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The aggregate cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities. [Refer: Subsidiaries [member]]" } }, "en-us": { "role": { "label": "Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities", "terseLabel": "Transactions with subsidiaries" } } }, "localname": "CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "auth_ref": [ "r59" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Categories of related parties [axis]" } } }, "localname": "CategoriesOfRelatedPartiesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureRelatedPartiesDetails", "http://www.genmab.com/role/DisclosureShareBasedInstrumentsRestrictedStockUnitProgramDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ChangesInEquity": { "auth_ref": [ "r9" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity. [Refer: Equity]" } }, "en-us": { "role": { "label": "Increase (decrease) in equity", "negatedLabel": "Expenses related to capital increases" } } }, "localname": "ChangesInEquity", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ClassesOfAssetsAxis": { "auth_ref": [ "r67", "r69", "r111", "r123" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of assets [axis]" } } }, "localname": "ClassesOfAssetsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureLeasesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfAssetsMember": { "auth_ref": [ "r67", "r111", "r123" ], "lang": { "en": { "role": { "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used." } }, "en-us": { "role": { "label": "Assets [member]" } } }, "localname": "ClassesOfAssetsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureLeasesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ClassesOfFinancialAssetsAxis": { "auth_ref": [ "r148", "r149", "r165", "r172", "r173", "r174" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of financial assets [axis]" } } }, "localname": "ClassesOfFinancialAssetsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": { "auth_ref": [ "r54" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of property, plant and equipment [axis]" } } }, "localname": "ClassesOfPropertyPlantAndEquipmentAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureLeasesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfShareCapitalAxis": { "auth_ref": [ "r32" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of share capital [axis]" } } }, "localname": "ClassesOfShareCapitalAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfShareCapitalMember": { "auth_ref": [ "r32" ], "lang": { "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } }, "en-us": { "role": { "label": "Share capital [member]" } } }, "localname": "ClassesOfShareCapitalMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "ifrs-full_ComponentsOfEquityAxis": { "auth_ref": [ "r10" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Components of equity [axis]" } } }, "localname": "ComponentsOfEquityAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfChangesInEquity" ], "xbrltype": "stringItemType" }, "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]", "verboseLabel": "Amounts which will be re-classified to the income statement:" } } }, "localname": "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome" ], "xbrltype": "stringItemType" }, "ifrs-full_ComprehensiveIncome": { "auth_ref": [ "r4", "r36", "r94", "r96", "r97", "r102" ], "calculation": { "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } }, "en-us": { "role": { "label": "Comprehensive income", "terseLabel": "Total comprehensive income", "totalLabel": "Total comprehensive income" } } }, "localname": "ComprehensiveIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfChangesInEquity", "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CreditRiskMember": { "auth_ref": [ "r139", "r167", "r168", "r169" ], "lang": { "en": { "role": { "documentation": "This member stands for the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Credit risk" } } }, "localname": "CreditRiskMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CurrencyRiskMember": { "auth_ref": [ "r152", "r167", "r168", "r169", "r170" ], "lang": { "en": { "role": { "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Currency risk [member]", "terseLabel": "Currency risk" } } }, "localname": "CurrencyRiskMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CurrentAssets": { "auth_ref": [ "r25", "r97", "r98" ], "calculation": { "http://www.genmab.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } }, "en-us": { "role": { "label": "Current assets", "totalLabel": "Total current assets" } } }, "localname": "CurrentAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLeaseLiabilities": { "auth_ref": [ "r117" ], "calculation": { "http://www.genmab.com/role/DisclosureLeasesDetails": { "order": 2.0, "parentTag": "ifrs-full_LeaseLiabilities", "weight": 1.0 }, "http://www.genmab.com/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Current lease liabilities", "terseLabel": "Lease liabilities", "verboseLabel": "Current" } } }, "localname": "CurrentLeaseLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureLeasesDetails", "http://www.genmab.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLiabilities": { "auth_ref": [ "r26", "r97", "r100" ], "calculation": { "http://www.genmab.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "ifrs-full_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.\nEffective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } }, "en-us": { "role": { "label": "Current liabilities", "totalLabel": "Total current liabilities" } } }, "localname": "CurrentLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentProvisions": { "auth_ref": [ "r22" ], "calculation": { "http://www.genmab.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]" } }, "en-us": { "role": { "label": "Current provisions", "terseLabel": "Provisions" } } }, "localname": "CurrentProvisions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentTaxLiabilitiesCurrent": { "auth_ref": [ "r23" ], "calculation": { "http://www.genmab.com/role/StatementBalanceSheets": { "order": 5.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The current amount of current tax liabilities. [Refer: Current tax liabilities]" } }, "en-us": { "role": { "label": "Current tax liabilities, current", "terseLabel": "Corporate tax payable" } } }, "localname": "CurrentTaxLiabilitiesCurrent", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DepreciationRightofuseAssets": { "auth_ref": [ "r118" ], "lang": { "en": { "role": { "documentation": "The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]" } }, "en-us": { "role": { "label": "Depreciation, right-of-use assets", "terseLabel": "Depreciation charge of right-of-use assets" } } }, "localname": "DepreciationRightofuseAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureLeasesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory": { "auth_ref": [ "r13" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for fair value measurement. [Refer: At fair value [member]]" } }, "en-us": { "role": { "label": "Description of accounting policy for fair value measurement [text block]", "terseLabel": "Fair Value Measurement" } } }, "localname": "DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": { "auth_ref": [ "r13" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for financial instruments. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Description of accounting policy for financial instruments [text block]", "terseLabel": "Marketable Securities" } } }, "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates": { "auth_ref": [ "r13" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for investments in associates. [Refer: Associates [member]]" } }, "en-us": { "role": { "label": "Description of accounting policy for investment in associates [text block]", "terseLabel": "Other Investments" } } }, "localname": "DescriptionOfAccountingPolicyForInvestmentInAssociates", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory": { "auth_ref": [ "r13" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for segment reporting." } }, "en-us": { "role": { "label": "Description of accounting policy for segment reporting [text block]", "terseLabel": "Information about Geographical Areas" } } }, "localname": "DescriptionOfAccountingPolicyForSegmentReportingExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DilutedEarningsLossPerShare": { "auth_ref": [ "r64", "r65" ], "lang": { "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } }, "en-us": { "role": { "label": "Diluted earnings (loss) per share", "terseLabel": "Diluted net profit per share" } } }, "localname": "DilutedEarningsLossPerShare", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome" ], "xbrltype": "perShareItemType" }, "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of the basis used for the preparation of the financial statements." } }, "en-us": { "role": { "label": "Disclosure of basis of preparation of financial statements [text block]", "verboseLabel": "Basis of Presentation" } } }, "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfCreditRiskExposureLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of credit risk exposure [line items]" } } }, "localname": "DisclosureOfCreditRiskExposureLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfCreditRiskExposureTable": { "auth_ref": [ "r146" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the credit risk exposure." } }, "en-us": { "role": { "label": "Disclosure of credit risk exposure [table]" } } }, "localname": "DisclosureOfCreditRiskExposureTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDeferredTaxesExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of deferred taxes. [Refer: Deferred tax liabilities; Deferred tax assets]" } }, "en-us": { "role": { "label": "Disclosure of deferred taxes [text block]", "verboseLabel": "Schedule of components of the deferred tax asset" } } }, "localname": "DisclosureOfDeferredTaxesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureRevenueTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": { "auth_ref": [ "r138", "r145", "r150" ], "lang": { "en": { "role": { "documentation": "The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [text block]", "verboseLabel": "Financial Instruments" } } }, "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory": { "auth_ref": [ "r113" ], "lang": { "en": { "role": { "documentation": "The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers]" } }, "en-us": { "role": { "label": "Disclosure of disaggregation of revenue from contracts with customers [text block]", "terseLabel": "Schedule of revenue by type and collaboration partner under agreements" } } }, "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureRevenueTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of disaggregation of revenue from contracts with customers [line items]", "verboseLabel": "Revenue" } } }, "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureRevenueDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": { "auth_ref": [ "r113" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers." } }, "en-us": { "role": { "label": "Disclosure of disaggregation of revenue from contracts with customers [table]" } } }, "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureRevenueDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfEarningsPerShareExplanatory": { "auth_ref": [ "r66" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for earnings per share." } }, "en-us": { "role": { "label": "Disclosure of earnings per share [text block]", "terseLabel": "Schedule of Result Per Share" } } }, "localname": "DisclosureOfEarningsPerShareExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureRevenueTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": { "auth_ref": [ "r47" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for events after the reporting period." } }, "en-us": { "role": { "label": "Disclosure of events after reporting period [text block]", "terseLabel": "Subsequent Events to the Balance Sheet Date" } } }, "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureSubsequentEventsToBalanceSheetDate" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory": { "auth_ref": [ "r111" ], "lang": { "en": { "role": { "documentation": "The disclosure of the fair value measurement of assets." } }, "en-us": { "role": { "label": "Disclosure of fair value measurement of assets [text block]", "verboseLabel": "Schedule of marketable securities" } } }, "localname": "DisclosureOfFairValueMeasurementOfAssetsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of fair value measurement of assets [line items]" } } }, "localname": "DisclosureOfFairValueMeasurementOfAssetsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable": { "auth_ref": [ "r111" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the fair value measurement of assets." } }, "en-us": { "role": { "label": "Disclosure of fair value measurement of assets [table]" } } }, "localname": "DisclosureOfFairValueMeasurementOfAssetsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of finance income (cost). [Refer: Finance income (cost)]" } }, "en-us": { "role": { "label": "Disclosure of finance income (cost) [text block]", "terseLabel": "Financial Income and Expenses" } } }, "localname": "DisclosureOfFinanceIncomeExpenseExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpenses" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Instruments" } } }, "localname": "DisclosureOfFinancialInstrumentsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfLeasesExplanatory": { "auth_ref": [ "r124", "r125" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for leases." } }, "en-us": { "role": { "label": "Disclosure of leases [text block]", "terseLabel": "Leases" } } }, "localname": "DisclosureOfLeasesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureLeases" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events to the Balance Sheet Date" } } }, "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": { "auth_ref": [ "r127" ], "lang": { "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)." } }, "en-us": { "role": { "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]", "terseLabel": "Summary of RSUs activity" } } }, "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory": { "auth_ref": [ "r153" ], "lang": { "en": { "role": { "documentation": "The disclosure of the offsetting of financial assets and financial liabilities. [Refer: Financial assets; Financial liabilities]" } }, "en-us": { "role": { "label": "Disclosure of offsetting of financial assets and financial liabilities [text block]", "terseLabel": "Schedule of Financial Assets" } } }, "localname": "DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of quantitative information about right-of-use assets [line items]" } } }, "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureLeasesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable": { "auth_ref": [ "r123" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to right-of-use assets." } }, "en-us": { "role": { "label": "Disclosure of quantitative information about right-of-use assets [table]" } } }, "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureLeasesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfRelatedPartyExplanatory": { "auth_ref": [ "r60" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for related parties." } }, "en-us": { "role": { "label": "Disclosure of related party [text block]", "terseLabel": "Related Parties" } } }, "localname": "DisclosureOfRelatedPartyExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureRelatedParties" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory": { "auth_ref": [ "r33" ], "lang": { "en": { "role": { "documentation": "The disclosure of reserves within equity. [Refer: Other reserves [member]]" } }, "en-us": { "role": { "label": "Disclosure of reserves within equity [text block]", "terseLabel": "Schedule of changes in share capital" } } }, "localname": "DisclosureOfReservesAndOtherEquityInterestExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory": { "auth_ref": [ "r115", "r116" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for revenue from contracts with customers." } }, "en-us": { "role": { "label": "Disclosure of revenue from contracts with customers [text block]", "terseLabel": "Revenue" } } }, "localname": "DisclosureOfRevenueFromContractsWithCustomersExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureRevenue" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": { "auth_ref": [ "r126" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for share-based payment arrangements." } }, "en-us": { "role": { "label": "Disclosure of share-based payment arrangements [text block]", "verboseLabel": "Share-Based Instruments" } } }, "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstruments" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": { "auth_ref": [ "r14" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for significant accounting policies applied by the entity." } }, "en-us": { "role": { "label": "Disclosure of significant accounting policies [text block]", "terseLabel": "Nature of Business and Accounting Policies" } } }, "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Instruments" } } }, "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]" } } }, "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsRestrictedStockUnitProgramDetails", "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails", "http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": { "auth_ref": [ "r127" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements." } }, "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [table]" } } }, "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsRestrictedStockUnitProgramDetails", "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails", "http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Parties" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of transactions between related parties [line items]" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": { "auth_ref": [ "r59" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to transactions between related parties." } }, "en-us": { "role": { "label": "Disclosure of transactions between related parties [table]" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTreasurySharesExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of treasury shares. [Refer: Treasury shares]" } }, "en-us": { "role": { "label": "Disclosure of treasury shares [text block]", "terseLabel": "Schedule Of Treasury Shares" } } }, "localname": "DisclosureOfTreasurySharesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "auth_ref": [ "r83", "r84" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } }, "en-us": { "role": { "label": "Effect of exchange rate changes on cash and cash equivalents", "terseLabel": "Exchange rate adjustments" } } }, "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EmployeeBenefitsExpense": { "auth_ref": [ "r1", "r3", "r45" ], "calculation": { "http://www.genmab.com/role/DisclosureResultsForYearStaffCostsDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment." } }, "en-us": { "role": { "label": "Employee benefits expense" } } }, "localname": "EmployeeBenefitsExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "monetaryItemType" }, "ifrs-full_EntitysTotalForExternalCreditGradesMember": { "auth_ref": [ "r146", "r151", "r176", "r179", "r181" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'External credit grades' axis if no other member is used." } }, "en-us": { "role": { "label": "Entity's total for external credit grades [member]" } } }, "localname": "EntitysTotalForExternalCreditGradesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_EntitysTotalForRelatedPartiesMember": { "auth_ref": [ "r59" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } }, "en-us": { "role": { "label": "Entity's total for related parties [member]" } } }, "localname": "EntitysTotalForRelatedPartiesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureRelatedPartiesDetails", "http://www.genmab.com/role/DisclosureShareBasedInstrumentsRestrictedStockUnitProgramDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Equity": { "auth_ref": [ "r24", "r29", "r93", "r95", "r108", "r109", "r110" ], "calculation": { "http://www.genmab.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } }, "en-us": { "role": { "label": "Equity", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "totalLabel": "Total shareholders' equity" } } }, "localname": "Equity", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementBalanceSheets", "http://www.genmab.com/role/StatementStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityAndLiabilities": { "auth_ref": [ "r24" ], "calculation": { "http://www.genmab.com/role/StatementBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } }, "en-us": { "role": { "label": "Equity and liabilities", "totalLabel": "Total shareholders' equity and liabilities" } } }, "localname": "EquityAndLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity and liabilities [abstract]", "terseLabel": "SHAREHOLDERS' EQUITY AND LIABILITIES" } } }, "localname": "EquityAndLiabilitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "ifrs-full_EquityMember": { "auth_ref": [ "r10" ], "lang": { "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } }, "en-us": { "role": { "label": "Equity [member]" } } }, "localname": "EquityMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": { "auth_ref": [ "r129" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets." } }, "en-us": { "role": { "label": "Expense from share-based payment transactions in which goods or services received did not qualify for recognition as assets", "terseLabel": "Share-based compensation expenses" } } }, "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed": { "auth_ref": [ "r120" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of the expense relating to short-term leases accounted for applying paragraph 6 of IFRS 16. This expense need not include the expense relating to leases with a lease term of one month or less. Short-term lease is a lease that, at the commencement date, has a lease term of 12 months or less. A lease that contains a purchase option is not a short-term lease." } }, "en-us": { "role": { "label": "Expense relating to short-term leases for which recognition exemption has been used", "terseLabel": "Expense relating to short-term leases" } } }, "localname": "ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureLeasesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ExternalCreditGradesAxis": { "auth_ref": [ "r146", "r151", "r176", "r179", "r181" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "External credit grades [axis]" } } }, "localname": "ExternalCreditGradesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_FinanceCosts": { "auth_ref": [ "r38" ], "calculation": { "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "order": 1.0, "parentTag": "ifrs-full_FinanceIncomeCost", "weight": -1.0 }, "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of costs associated with financing activities of the entity." } }, "en-us": { "role": { "label": "Finance costs", "negatedLabel": "Financial expenses", "negatedTotalLabel": "Total financial expenses" } } }, "localname": "FinanceCosts", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails", "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinanceIncome": { "auth_ref": [ "r40" ], "calculation": { "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "order": 2.0, "parentTag": "ifrs-full_FinanceIncomeCost", "weight": 1.0 }, "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income associated with interest and other financing activities of the entity." } }, "en-us": { "role": { "label": "Financial income", "totalLabel": "Total financial income" } } }, "localname": "FinanceIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails", "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinanceIncomeCost": { "auth_ref": [ "r40" ], "calculation": { "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income or cost associated with interest and other financing activities of the entity." } }, "en-us": { "role": { "label": "Finance income (cost)", "totalLabel": "Net financial items" } } }, "localname": "FinanceIncomeCost", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialAssets": { "auth_ref": [ "r137", "r142", "r143", "r146", "r147" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]" } }, "en-us": { "role": { "label": "Financial assets" } } }, "localname": "FinancialAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialAssetsMember": { "auth_ref": [ "r148", "r149", "r165", "r172", "r173", "r174" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Financial assets, class [member]" } } }, "localname": "FinancialAssetsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_GeneralAndAdministrativeExpense": { "auth_ref": [ "r12" ], "calculation": { "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense relating to general and administrative activities of the entity." } }, "en-us": { "role": { "label": "General and administrative expense", "negatedLabel": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Profit or loss [abstract]", "terseLabel": "Income Statement" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome" ], "xbrltype": "stringItemType" }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "auth_ref": [ "r39", "r48", "r50", "r51", "r61", "r106", "r155" ], "calculation": { "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]" } }, "en-us": { "role": { "label": "Tax expense (income), continuing operations", "negatedLabel": "Corporate tax" } } }, "localname": "IncomeTaxExpenseContinuingOperations", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome": { "auth_ref": [ "r41", "r49" ], "calculation": { "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome": { "order": 5.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of income tax relating to amounts recognised in other comprehensive income in relation to exchange differences on the translation of financial statements of foreign operations. [Refer: Other comprehensive income; Reserve of exchange differences on translation]" } }, "en-us": { "role": { "label": "Income tax relating to exchange differences on translation of other comprehensive income", "negatedLabel": "Excess tax benefits" } } }, "localname": "IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member": { "auth_ref": [ "r114" ], "lang": { "en": { "role": { "documentation": "This member stands for IFRS 15 Revenue with Contracts with Customers." } }, "en-us": { "role": { "label": "Increase (decrease) due to application of IFRS 15 [member]" } } }, "localname": "IncreaseDecreaseDueToApplicationOfIFRS15Member", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": { "auth_ref": [ "r88" ], "calculation": { "http://www.genmab.com/role/StatementStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } }, "en-us": { "role": { "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes", "totalLabel": "Change in cash and cash equivalents" } } }, "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseInWorkingCapital": { "auth_ref": [ "r82" ], "calculation": { "http://www.genmab.com/role/StatementStatementsOfCashFlows": { "order": 4.0, "parentTag": "gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in working capital." } }, "en-us": { "role": { "label": "Increase (decrease) in working capital", "negatedTerseLabel": "Changes in operating assets and liabilities" } } }, "localname": "IncreaseDecreaseInWorkingCapital", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity": { "auth_ref": [ "r9" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the exercise of warrants." } }, "en-us": { "role": { "label": "Increase (decrease) through exercise of warrants, equity", "terseLabel": "Exercise of warrants" } } }, "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquity", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "auth_ref": [ "r8" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } }, "en-us": { "role": { "label": "Increase (decrease) through share-based payment transactions, equity", "terseLabel": "Share-based compensation expenses" } } }, "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r18", "r70" ], "calculation": { "http://www.genmab.com/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } }, "en-us": { "role": { "label": "Intangible assets other than goodwill", "terseLabel": "Intangible assets" } } }, "localname": "IntangibleAssetsOtherThanGoodwill", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestExpenseOnLeaseLiabilities": { "auth_ref": [ "r119" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Interest expense on lease liabilities", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenseOnLeaseLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureLeasesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestPaidClassifiedAsOperatingActivities": { "auth_ref": [ "r85" ], "calculation": { "http://www.genmab.com/role/StatementStatementsOfCashFlows": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for interest paid, classified as operating activities." } }, "en-us": { "role": { "label": "Interest paid, classified as operating activities", "negatedTerseLabel": "Interest paid" } } }, "localname": "InterestPaidClassifiedAsOperatingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestReceivedClassifiedAsOperatingActivities": { "auth_ref": [ "r85" ], "calculation": { "http://www.genmab.com/role/StatementStatementsOfCashFlows": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from interest received, classified as operating activities." } }, "en-us": { "role": { "label": "Interest received, classified as operating activities", "terseLabel": "Interest received" } } }, "localname": "InterestReceivedClassifiedAsOperatingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InvestmentAccountedForUsingEquityMethod": { "auth_ref": [ "r19", "r107", "r157" ], "calculation": { "http://www.genmab.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]" } }, "en-us": { "role": { "label": "Investments accounted for using equity method", "verboseLabel": "Other investments" } } }, "localname": "InvestmentAccountedForUsingEquityMethod", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsOtherInvestmentsDetails", "http://www.genmab.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssueOfEquity": { "auth_ref": [ "r8" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase in equity through the issue of equity instruments." } }, "en-us": { "role": { "label": "Issue of equity", "verboseLabel": "Shares issued for cash" } } }, "localname": "IssueOfEquity", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssuedCapital": { "auth_ref": [ "r29" ], "calculation": { "http://www.genmab.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The nominal value of capital issued." } }, "en-us": { "role": { "label": "Issued capital", "terseLabel": "Share capital" } } }, "localname": "IssuedCapital", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssuedCapitalMember": { "auth_ref": [ "r10" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } }, "en-us": { "role": { "label": "Issued capital [member]" } } }, "localname": "IssuedCapitalMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_KeyManagementPersonnelOfEntityOrParentMember": { "auth_ref": [ "r58" ], "lang": { "en": { "role": { "documentation": "This member stands for those persons having authority and responsibility for planning, directing and controlling the activities of the entity, directly or indirectly, including any director (whether executive or otherwise) of that entity." } }, "en-us": { "role": { "label": "Board of Directors and Executive Management" } } }, "localname": "KeyManagementPersonnelOfEntityOrParentMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LeaseLiabilities": { "auth_ref": [ "r117" ], "calculation": { "http://www.genmab.com/role/DisclosureLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration." } }, "en-us": { "role": { "label": "Lease liabilities", "totalLabel": "Total lease liabilities" } } }, "localname": "LeaseLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureLeasesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease liabilities [abstract]", "terseLabel": "Lease Liabilities" } } }, "localname": "LeaseLiabilitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureLeasesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_Level1OfFairValueHierarchyMember": { "auth_ref": [ "r55", "r109" ], "lang": { "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date." } }, "en-us": { "role": { "label": "Level 1 of fair value hierarchy [member]" } } }, "localname": "Level1OfFairValueHierarchyMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Level2OfFairValueHierarchyMember": { "auth_ref": [ "r109" ], "lang": { "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly." } }, "en-us": { "role": { "label": "Level 2 of fair value hierarchy [member]" } } }, "localname": "Level2OfFairValueHierarchyMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Level3OfFairValueHierarchyMember": { "auth_ref": [ "r109" ], "lang": { "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability." } }, "en-us": { "role": { "label": "Level 3 of fair value hierarchy [member]" } } }, "localname": "Level3OfFairValueHierarchyMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LevelsOfFairValueHierarchyAxis": { "auth_ref": [ "r55", "r109" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Levels of fair value hierarchy [axis]" } } }, "localname": "LevelsOfFairValueHierarchyAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_Liabilities": { "auth_ref": [ "r24", "r108", "r109", "r110", "r156", "r161" ], "calculation": { "http://www.genmab.com/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } }, "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_MaximumExposureToCreditRisk": { "auth_ref": [ "r144", "r178" ], "lang": { "en": { "role": { "documentation": "The amount that best represents the maximum exposure to credit risk without taking into account any collateral held or other credit enhancements (for example, netting agreements that do not qualify for offset in accordance with IAS 32). [Refer: Credit risk [member]]" } }, "en-us": { "role": { "label": "Maximum exposure to credit risk", "terseLabel": "Maximum credit exposure" } } }, "localname": "MaximumExposureToCreditRisk", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_MaximumExposureToCreditRiskOfLoansOrReceivables": { "auth_ref": [ "r180" ], "lang": { "en": { "role": { "documentation": "The maximum exposure to the credit risk of loans or receivables. [Refer: Loans and receivables; Credit risk [member]; Maximum exposure to credit risk]" } }, "en-us": { "role": { "label": "Maximum exposure to credit risk of loans or receivables", "terseLabel": "Maximum credit exposure to receivables" } } }, "localname": "MaximumExposureToCreditRiskOfLoansOrReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_MeasurementAxis": { "auth_ref": [ "r73", "r74", "r108" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Measurement [axis]" } } }, "localname": "MeasurementAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_NetDeferredTaxAssets": { "auth_ref": [ "r52" ], "calculation": { "http://www.genmab.com/role/StatementBalanceSheets": { "order": 6.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of deferred tax assets net of deferred tax liabilities, when the absolute amount of deferred tax assets is greater than the absolute amount of deferred tax liabilities. [Refer: Deferred tax assets; Deferred tax liabilities]" } }, "en-us": { "role": { "label": "Net deferred tax assets", "terseLabel": "Deferred tax assets" } } }, "localname": "NetDeferredTaxAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NetForeignExchangeGain": { "auth_ref": [ "r16", "r56" ], "calculation": { "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "order": 1.0, "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The net gain arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]" } }, "en-us": { "role": { "label": "Net foreign exchange gain", "terseLabel": "Foreign exchange rate gain, net" } } }, "localname": "NetForeignExchangeGain", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NetForeignExchangeLoss": { "auth_ref": [ "r16", "r56" ], "calculation": { "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "order": 1.0, "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The net loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]" } }, "en-us": { "role": { "label": "Net foreign exchange loss", "negatedLabel": "Foreign exchange rate loss, net" } } }, "localname": "NetForeignExchangeLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentAssets": { "auth_ref": [ "r25", "r97", "r99" ], "calculation": { "http://www.genmab.com/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } }, "en-us": { "role": { "label": "Non-current assets", "totalLabel": "Total non-current assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentLeaseLiabilities": { "auth_ref": [ "r117" ], "calculation": { "http://www.genmab.com/role/DisclosureLeasesDetails": { "order": 1.0, "parentTag": "ifrs-full_LeaseLiabilities", "weight": 1.0 }, "http://www.genmab.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Non-current lease liabilities", "terseLabel": "Lease liabilities", "verboseLabel": "Non-current" } } }, "localname": "NoncurrentLeaseLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureLeasesDetails", "http://www.genmab.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentLiabilities": { "auth_ref": [ "r26", "r97", "r101" ], "calculation": { "http://www.genmab.com/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "ifrs-full_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } }, "en-us": { "role": { "label": "Non-current liabilities", "totalLabel": "Total non-current liabilities" } } }, "localname": "NoncurrentLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentProvisions": { "auth_ref": [ "r22" ], "calculation": { "http://www.genmab.com/role/StatementBalanceSheets": { "order": 3.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]" } }, "en-us": { "role": { "label": "Non-current provisions", "verboseLabel": "Provisions" } } }, "localname": "NoncurrentProvisions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentReceivables": { "auth_ref": [ "r20", "r28" ], "calculation": { "http://www.genmab.com/role/StatementBalanceSheets": { "order": 5.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of non-current trade receivables and non-current other receivables. [Refer: Non-current trade receivables; Other non-current receivables]" } }, "en-us": { "role": { "label": "Trade and other non-current receivables", "terseLabel": "Receivables" } } }, "localname": "NoncurrentReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": { "auth_ref": [ "r127", "r128" ], "lang": { "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of other equity instruments granted in share-based payment arrangement", "terseLabel": "Granted" } } }, "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsRestrictedStockUnitProgramDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": { "auth_ref": [ "r127" ], "lang": { "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of other equity instruments exercised or vested in share-based payment arrangement", "terseLabel": "Vested" } } }, "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsRestrictedStockUnitProgramDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": { "auth_ref": [ "r127" ], "lang": { "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of other equity instruments forfeited in share-based payment arrangement", "negatedLabel": "Forfeited/Cancelled" } } }, "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsRestrictedStockUnitProgramDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": { "auth_ref": [ "r127" ], "lang": { "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of other equity instruments outstanding in share-based payment arrangement", "periodEndLabel": "Outstanding at end of period", "periodStartLabel": "Outstanding at beginning of period" } } }, "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsRestrictedStockUnitProgramDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfSharesOutstanding": { "auth_ref": [ "r31" ], "lang": { "en": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]" } }, "en-us": { "role": { "label": "Number of shares outstanding", "periodEndLabel": "Number of shares, at end of period", "periodStartLabel": "Number of shares, at beginning of period" } } }, "localname": "NumberOfSharesOutstanding", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfChangesInEquity" ], "xbrltype": "sharesItemType" }, "ifrs-full_OperatingExpense": { "auth_ref": [ "r40" ], "calculation": { "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of all operating expenses." } }, "en-us": { "role": { "label": "Operating expense", "negatedTotalLabel": "Operating expenses" } } }, "localname": "OperatingExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OrdinarySharesMember": { "auth_ref": [ "r32", "r64" ], "lang": { "en": { "role": { "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used." } }, "en-us": { "role": { "label": "Ordinary shares [member]" } } }, "localname": "OrdinarySharesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "ifrs-full_OtherComprehensiveIncome": { "auth_ref": [ "r7", "r35", "r42", "r104" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]" } }, "en-us": { "role": { "label": "Other comprehensive income", "terseLabel": "Other comprehensive income" } } }, "localname": "OtherComprehensiveIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other comprehensive income [abstract]", "terseLabel": "Other comprehensive income:" } } }, "localname": "OtherComprehensiveIncomeAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome" ], "xbrltype": "stringItemType" }, "ifrs-full_OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation": { "auth_ref": [ "r27", "r43" ], "calculation": { "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome": { "order": 6.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of other comprehensive income, before tax, after reclassification adjustments, related to exchange differences on translation of financial statements of foreign operations. [Refer: Other comprehensive income, before tax]" } }, "en-us": { "role": { "label": "Other comprehensive income, before tax, exchange differences on translation", "terseLabel": "Adjustment of foreign currency fluctuations on subsidiaries" } } }, "localname": "OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxChangeInFairValueOfFinancialLiabilityAttributableToChangeInCreditRiskOfLiability": { "auth_ref": [ "r27", "r42" ], "calculation": { "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, related to changes in the fair value of financial liabilities attributable to the changes in the credit risk of those liabilities. [Refer: Other comprehensive income; Credit risk [member]; Financial liabilities]" } }, "en-us": { "role": { "label": "Other comprehensive income, net of tax, change in fair value of financial liability attributable to change in credit risk of liability", "terseLabel": "Fair value adjustments during the period" } } }, "localname": "OtherComprehensiveIncomeNetOfTaxChangeInFairValueOfFinancialLiabilityAttributableToChangeInCreditRiskOfLiability", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": { "auth_ref": [ "r27", "r42" ], "calculation": { "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Other comprehensive income, net of tax, exchange differences on translation", "terseLabel": "Adjustment of foreign currency fluctuations on subsidiaries" } } }, "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherCurrentLiabilities": { "auth_ref": [ "r24" ], "calculation": { "http://www.genmab.com/role/StatementBalanceSheets": { "order": 6.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]" } }, "en-us": { "role": { "label": "Other current liabilities" } } }, "localname": "OtherCurrentLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "monetaryItemType" }, "ifrs-full_OtherCurrentPayables": { "auth_ref": [ "r24" ], "calculation": { "http://www.genmab.com/role/StatementBalanceSheets": { "order": 4.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other current payables", "verboseLabel": "Other payables" } } }, "localname": "OtherCurrentPayables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherNoncurrentLiabilities": { "auth_ref": [ "r24" ], "calculation": { "http://www.genmab.com/role/StatementBalanceSheets": { "order": 5.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]" } }, "en-us": { "role": { "label": "Other non-current liabilities" } } }, "localname": "OtherNoncurrentLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "monetaryItemType" }, "ifrs-full_OtherNoncurrentPayables": { "auth_ref": [ "r24" ], "calculation": { "http://www.genmab.com/role/StatementBalanceSheets": { "order": 4.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current payables that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other non-current payables", "verboseLabel": "Other payables" } } }, "localname": "OtherNoncurrentPayables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherReserves": { "auth_ref": [ "r29" ], "calculation": { "http://www.genmab.com/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]" } }, "en-us": { "role": { "label": "Other reserves", "terseLabel": "Other reserves" } } }, "localname": "OtherReserves", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PaymentsForShareIssueCosts": { "auth_ref": [ "r80" ], "calculation": { "http://www.genmab.com/role/StatementStatementsOfCashFlows": { "order": 6.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for share issue costs." } }, "en-us": { "role": { "label": "Payments for share issue costs", "negatedLabel": "Costs related to issuance of shares" } } }, "localname": "PaymentsForShareIssueCosts", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "auth_ref": [ "r79" ], "calculation": { "http://www.genmab.com/role/StatementStatementsOfCashFlows": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Payments of lease liabilities, classified as financing activities", "negatedLabel": "Principal elements of lease payments" } } }, "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PresentationOfLeasesForLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases" } } }, "localname": "PresentationOfLeasesForLesseeAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_ProceedsFromExerciseOfWarrants": { "auth_ref": [ "r80" ], "calculation": { "http://www.genmab.com/role/StatementStatementsOfCashFlows": { "order": 4.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from the exercise of share purchase warrants." } }, "en-us": { "role": { "label": "Proceeds From Exercise Of Warrants", "terseLabel": "Warrants exercised", "verboseLabel": "Exercise of warrants" } } }, "localname": "ProceedsFromExerciseOfWarrants", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails", "http://www.genmab.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromIssueOfOrdinaryShares": { "auth_ref": [ "r80" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]" } }, "en-us": { "role": { "label": "Proceeds from issue of ordinary shares", "verboseLabel": "Proceeds from sale of shares" } } }, "localname": "ProceedsFromIssueOfOrdinaryShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsOtherInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromIssuingShares": { "auth_ref": [ "r78" ], "calculation": { "http://www.genmab.com/role/StatementStatementsOfCashFlows": { "order": 5.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from issuing shares." } }, "en-us": { "role": { "label": "Proceeds from issuing shares", "terseLabel": "Shares issued for cash" } } }, "localname": "ProceedsFromIssuingShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod": { "auth_ref": [ "r77" ], "calculation": { "http://www.genmab.com/role/StatementStatementsOfCashFlows": { "order": 6.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from sales of investments accounted for using the equity method. [Refer: Investments accounted for using equity method]" } }, "en-us": { "role": { "label": "Proceeds from sales of investments accounted for using equity method", "terseLabel": "Other investments sold" } } }, "localname": "ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod": { "auth_ref": [ "r77" ], "calculation": { "http://www.genmab.com/role/StatementStatementsOfCashFlows": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from sales of investments other than investments accounted for using the equity method. [Refer: Investments accounted for using equity method; Investments other than investments accounted for using equity method]" } }, "en-us": { "role": { "label": "Proceeds from sales of investments other than investments accounted for using equity method", "terseLabel": "Marketable securities sold" } } }, "localname": "ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLoss": { "auth_ref": [ "r6", "r34", "r81", "r94", "r96", "r97", "r156", "r159", "r166", "r175" ], "calculation": { "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome": { "order": 4.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Profit (loss)", "terseLabel": "Net profit", "totalLabel": "Net profit" } } }, "localname": "ProfitLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfChangesInEquity", "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossBeforeTax": { "auth_ref": [ "r1", "r2", "r130", "r156", "r159" ], "calculation": { "http://www.genmab.com/role/StatementStatementsOfCashFlows": { "order": 1.0, "parentTag": "gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems", "weight": 1.0 }, "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit (loss) before tax", "totalLabel": "Net profit before tax", "verboseLabel": "Net profit before tax" } } }, "localname": "ProfitLossBeforeTax", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfCashFlows", "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossFromOperatingActivities": { "auth_ref": [ "r40", "r63" ], "calculation": { "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome": { "order": 3.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit (loss) from operating activities", "totalLabel": "Operating profit" } } }, "localname": "ProfitLossFromOperatingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PropertyPlantAndEquipment": { "auth_ref": [ "r17", "r53" ], "calculation": { "http://www.genmab.com/role/StatementBalanceSheets": { "order": 3.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period." } }, "en-us": { "role": { "label": "Property, plant and equipment", "terseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PropertyPlantAndEquipmentMember": { "auth_ref": [ "r54", "r68", "r123" ], "lang": { "en": { "role": { "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Property, plant and equipment [member]" } } }, "localname": "PropertyPlantAndEquipmentMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureLeasesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": { "auth_ref": [ "r76" ], "calculation": { "http://www.genmab.com/role/StatementStatementsOfCashFlows": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Purchase of intangible assets, classified as investing activities", "negatedLabel": "Investment in intangible assets" } } }, "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod": { "auth_ref": [ "r77" ], "calculation": { "http://www.genmab.com/role/StatementStatementsOfCashFlows": { "order": 5.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for the purchase of interests in investments accounted for using the equity method. [Refer: Investments accounted for using equity method]" } }, "en-us": { "role": { "label": "Purchase of interests in investments accounted for using equity method", "negatedLabel": "Other investments bought" } } }, "localname": "PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod": { "auth_ref": [ "r77" ], "calculation": { "http://www.genmab.com/role/StatementStatementsOfCashFlows": { "order": 4.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for the purchase of investments other than investments accounted for using equity method. [Refer: Investments accounted for using equity method; Investments other than investments accounted for using equity method]" } }, "en-us": { "role": { "label": "Purchase of investments other than investments accounted for using equity method", "negatedLabel": "Marketable securities bought" } } }, "localname": "PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "auth_ref": [ "r76" ], "calculation": { "http://www.genmab.com/role/StatementStatementsOfCashFlows": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Purchase of property, plant and equipment, classified as investing activities", "negatedLabel": "Investment in tangible assets" } } }, "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PurchaseOfTreasuryShares": { "auth_ref": [ "r9" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The decrease in equity resulting from the purchase of treasury shares. [Refer: Treasury shares]" } }, "en-us": { "role": { "label": "Purchase of treasury shares", "negatedLabel": "Purchase of treasury shares", "terseLabel": "Acquisition of treasury shares" } } }, "localname": "PurchaseOfTreasuryShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails", "http://www.genmab.com/role/StatementStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax": { "auth_ref": [ "r44", "r134", "r136", "r177" ], "calculation": { "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome": { "order": 3.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of reclassification adjustments related to cash flow hedges, net of tax. Reclassification adjustments are amounts reclassified to profit (loss) in the current period that were recognised in other comprehensive income in the current or previous periods. [Refer: Cash flow hedges [member]; Other comprehensive income]" } }, "en-us": { "role": { "label": "Reclassification adjustments on cash flow hedges, net of tax", "negatedLabel": "Fair value adjustments reclassified to the income statement to financial income" } } }, "localname": "ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Reconciliation of changes in fair value measurement, assets [abstract]" } } }, "localname": "ReconciliationOfChangesInFairValueMeasurementAssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_RentDeferredIncomeClassifiedAsCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://www.genmab.com/role/StatementBalanceSheets": { "order": 3.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of rent deferred income classified as current. [Refer: Rent deferred income]" } }, "en-us": { "role": { "label": "Rent deferred income classified as current", "terseLabel": "Deferred revenue" } } }, "localname": "RentDeferredIncomeClassifiedAsCurrent", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RentDeferredIncomeClassifiedAsNoncurrent": { "auth_ref": [ "r30" ], "calculation": { "http://www.genmab.com/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of rent deferred income classified as non-current. [Refer: Rent deferred income]" } }, "en-us": { "role": { "label": "Rent deferred income classified as non-current", "terseLabel": "Deferred revenue" } } }, "localname": "RentDeferredIncomeClassifiedAsNoncurrent", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ResearchAndDevelopmentExpense": { "auth_ref": [ "r71" ], "calculation": { "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome": { "order": 3.0, "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss." } }, "en-us": { "role": { "label": "Research and development expense", "negatedLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": { "auth_ref": [ "r11", "r57" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Translation reserves" } } }, "localname": "ReserveOfExchangeDifferencesOnTranslationMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_RestatedMember": { "auth_ref": [ "r5", "r15", "r90", "r91", "r92", "r166" ], "lang": { "en": { "role": { "documentation": "This member stands for the information currently stated in the financial statements. It also represents the standard value for the 'Retrospective application and retrospective restatement' and 'Departure from requirement of IFRS' axes if no other member is used." } }, "en-us": { "role": { "label": "Currently stated [member]" } } }, "localname": "RestatedMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_RetainedEarnings": { "auth_ref": [ "r29", "r46" ], "calculation": { "http://www.genmab.com/role/StatementBalanceSheets": { "order": 3.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } }, "en-us": { "role": { "label": "Retained earnings", "verboseLabel": "Retained earnings" } } }, "localname": "RetainedEarnings", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RetainedEarningsMember": { "auth_ref": [ "r10", "r11" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } }, "en-us": { "role": { "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis": { "auth_ref": [ "r5", "r90", "r91", "r92" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Retrospective application and retrospective restatement [axis]" } } }, "localname": "RetrospectiveApplicationAndRetrospectiveRestatementAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfChangesInEquity" ], "xbrltype": "stringItemType" }, "ifrs-full_Revenue": { "auth_ref": [ "r1", "r2", "r37", "r97", "r103", "r130", "r154", "r158", "r162", "r163", "r164" ], "calculation": { "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims." } }, "en-us": { "role": { "label": "Revenue.", "terseLabel": "Revenue" } } }, "localname": "Revenue", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue" } } }, "localname": "RevenueAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_RevenueFromContractsWithCustomers": { "auth_ref": [ "r112", "r113" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity\u2019s ordinary activities in exchange for consideration." } }, "en-us": { "role": { "label": "Revenue from contracts with customers", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractsWithCustomers", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureRevenueDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RightofuseAssets": { "auth_ref": [ "r122" ], "calculation": { "http://www.genmab.com/role/StatementBalanceSheets": { "order": 4.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee." } }, "en-us": { "role": { "label": "Right-of-use assets", "verboseLabel": "Right-of-use assets" } } }, "localname": "RightofuseAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureLeasesDetails", "http://www.genmab.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SaleOrIssueOfTreasuryShares": { "auth_ref": [ "r9" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase in equity resulting from the sale or issue of treasury shares. [Refer: Treasury shares]" } }, "en-us": { "role": { "label": "Sale or issue of treasury shares", "terseLabel": "Treasury shares issued" } } }, "localname": "SaleOrIssueOfTreasuryShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsRestrictedStockUnitProgramDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r40" ], "calculation": { "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense relating to selling, general and administrative activities of the entity." } }, "en-us": { "role": { "label": "Selling, general and administrative expense", "negatedLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SharePremium": { "auth_ref": [ "r29" ], "calculation": { "http://www.genmab.com/role/StatementBalanceSheets": { "order": 4.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value." } }, "en-us": { "role": { "label": "Share premium", "terseLabel": "Share premium" } } }, "localname": "SharePremium", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SharePremiumMember": { "auth_ref": [ "r10" ], "lang": { "en": { "role": { "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value." } }, "en-us": { "role": { "label": "Share premium [Member]" } } }, "localname": "SharePremiumMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_SharebasedPaymentArrangementsMember": { "auth_ref": [ "r127" ], "lang": { "en": { "role": { "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used." } }, "en-us": { "role": { "label": "Share-based payment arrangements [member]" } } }, "localname": "SharebasedPaymentArrangementsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsRestrictedStockUnitProgramDetails", "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails", "http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents": { "auth_ref": [ "r88" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "A classification of cash equivalents representing short-term investments. [Refer: Cash equivalents]" } }, "en-us": { "role": { "label": "Short-term investments, classified as cash equivalents", "terseLabel": "Short-term marketable securities" } } }, "localname": "ShorttermInvestmentsClassifiedAsCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STATEMENTS OF CASH FLOWS" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STATEMENTS OF CHANGES IN EQUITY" } } }, "localname": "StatementOfChangesInEquityAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Statement of changes in equity [line items]", "terseLabel": "STATEMENT OF CHANGES IN EQUITY" } } }, "localname": "StatementOfChangesInEquityLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfChangesInEquity" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityTable": { "auth_ref": [ "r10" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } }, "en-us": { "role": { "label": "Statement of changes in equity [table]" } } }, "localname": "StatementOfChangesInEquityTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfChangesInEquity" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of comprehensive income [abstract]", "terseLabel": "Statement of Comprehensive Income" } } }, "localname": "StatementOfComprehensiveIncomeAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BALANCE SHEETS" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STATEMENTS OF COMPREHENSIVE INCOME" } } }, "localname": "StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_TradeAndOtherCurrentReceivables": { "auth_ref": [ "r20", "r28" ], "calculation": { "http://www.genmab.com/role/StatementBalanceSheets": { "order": 3.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]" } }, "en-us": { "role": { "label": "Trade and other current receivables", "terseLabel": "Receivables" } } }, "localname": "TradeAndOtherCurrentReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TreasuryShares": { "auth_ref": [ "r29", "r62" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "An entity\u2019s own equity instruments, held by the entity or other members of the consolidated group." } }, "en-us": { "role": { "label": "Treasury shares", "terseLabel": "Treasury shares" } } }, "localname": "TreasuryShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsRestrictedStockUnitProgramDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TypesOfRisksAxis": { "auth_ref": [ "r131", "r140", "r141", "r167", "r168", "r169", "r171" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Types of risks [axis]" } } }, "localname": "TypesOfRisksAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_TypesOfRisksMember": { "auth_ref": [ "r131", "r140", "r141", "r167", "r168", "r169", "r171" ], "lang": { "en": { "role": { "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used." } }, "en-us": { "role": { "label": "Risks [member]" } } }, "localname": "TypesOfRisksMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": { "auth_ref": [ "r127" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Types of share-based payment arrangements [axis]" } } }, "localname": "TypesOfSharebasedPaymentArrangementsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsRestrictedStockUnitProgramDetails", "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails", "http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails" ], "xbrltype": "stringItemType" }, "srt_CurrencyAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Currency [Axis]" } } }, "localname": "CurrencyAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.genmab.com/role/DisclosureLeasesDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.genmab.com/role/DisclosureLeasesDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "10", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_10_e&doctype=Standard", "URIDate": "2021-03-24" }, "r1": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "102", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_102&doctype=Standard", "URIDate": "2021-03-24" }, "r10": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106&doctype=Standard", "URIDate": "2021-03-24" }, "r100": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r101": { "Clause": "iv", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r102": { "Clause": "ix", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r103": { "Clause": "v", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r104": { "Clause": "viii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r105": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r106": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "g", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r107": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B16", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B16&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r108": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2021-03-24" }, "r109": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2021-03-24" }, "r11": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "108", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_108&doctype=Standard", "URIDate": "2021-03-24" }, "r110": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2021-03-24" }, "r111": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93&doctype=Standard", "URIDate": "2021-03-24" }, "r112": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "113", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_113_a&doctype=Standard", "URIDate": "2021-03-24" }, "r113": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "114", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_114&doctype=Standard", "URIDate": "2021-03-24" }, "r114": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "C8", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_C8_a&doctype=Appendix&subtype=C", "URIDate": "2021-03-24" }, "r115": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS15_g110-129_TI", "URIDate": "2021-03-24" }, "r116": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Section": "Presentation", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS15_g105-109_TI", "URIDate": "2021-03-24" }, "r117": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "47", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2021-03-24" }, "r118": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_a&doctype=Standard", "URIDate": "2021-03-24" }, "r119": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_b&doctype=Standard", "URIDate": "2021-03-24" }, "r12": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "112", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_112_c&doctype=Standard", "URIDate": "2021-03-24" }, "r120": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_c&doctype=Standard", "URIDate": "2021-03-24" }, "r121": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "h", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_h&doctype=Standard", "URIDate": "2021-03-24" }, "r122": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "j", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_j&doctype=Standard", "URIDate": "2021-03-24" }, "r123": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53&doctype=Standard", "URIDate": "2021-03-24" }, "r124": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI", "URIDate": "2021-03-24" }, "r125": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Section": "Presentation", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI", "URIDate": "2021-03-24" }, "r126": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "44", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_44&doctype=Standard", "URIDate": "2021-03-24" }, "r127": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard", "URIDate": "2021-03-24" }, "r128": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "47", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2021-03-24" }, "r129": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "51", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_51_a&doctype=Standard", "URIDate": "2021-03-24" }, "r13": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "117", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_117_b&doctype=Standard", "URIDate": "2021-03-24" }, "r130": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "5", "Paragraph": "33", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2021-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2021-03-24" }, "r131": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "21C", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_21C&doctype=Standard", "URIDate": "2021-03-24" }, "r132": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "24A", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_24A&doctype=Standard", "URIDate": "2021-03-24" }, "r133": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "24B", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_24B&doctype=Standard", "URIDate": "2021-03-24" }, "r134": { "Clause": "iv", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "24C", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_24C_b_iv&doctype=Standard", "URIDate": "2021-03-24" }, "r135": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "24C", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_24C&doctype=Standard", "URIDate": "2021-03-24" }, "r136": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "24E", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_24E_a&doctype=Standard", "URIDate": "2021-03-24" }, "r137": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "25", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_25&doctype=Standard", "URIDate": "2021-03-24" }, "r138": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "31", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_31&doctype=Standard", "URIDate": "2021-03-24" }, "r139": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "32", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_32&doctype=Standard", "URIDate": "2021-03-24" }, "r14": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "117", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_117&doctype=Standard", "URIDate": "2021-03-24" }, "r140": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "33", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_33&doctype=Standard", "URIDate": "2021-03-24" }, "r141": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "34", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_34&doctype=Standard", "URIDate": "2021-03-24" }, "r142": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35H", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2021-03-24" }, "r143": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35I", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35I&doctype=Standard", "URIDate": "2021-03-24" }, "r144": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35K", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35K_a&doctype=Standard", "URIDate": "2021-03-24" }, "r145": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35K", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2021-03-24" }, "r146": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35M", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2021-03-24" }, "r147": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35N", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35N&doctype=Standard", "URIDate": "2021-03-24" }, "r148": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "42I", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_42I&doctype=Standard", "URIDate": "2021-03-24" }, "r149": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "6", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_6&doctype=Standard", "URIDate": "2021-03-24" }, "r15": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "20", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_20_d&doctype=Standard", "URIDate": "2021-03-24" }, "r150": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "7", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_7&doctype=Standard", "URIDate": "2021-03-24" }, "r151": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "IG20C", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_IG20C&doctype=Implementation%20Guidance", "URIDate": "2021-03-24" }, "r152": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Section": "Defined terms", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA_TI", "URIDate": "2021-03-24" }, "r153": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Section": "Offsetting financial assets and financial liabilities", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS07_g13A-13F_TI", "URIDate": "2021-03-24" }, "r154": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_a&doctype=Standard", "URIDate": "2021-03-24" }, "r155": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "h", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2021-03-24" }, "r156": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23&doctype=Standard", "URIDate": "2021-03-24" }, "r157": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "24", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2021-03-24" }, "r158": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_a&doctype=Standard", "URIDate": "2021-03-24" }, "r159": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2021-03-24" }, "r16": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "35", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_35&doctype=Standard", "URIDate": "2021-03-24" }, "r160": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2021-03-24" }, "r161": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2021-03-24" }, "r162": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "32", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_32&doctype=Standard", "URIDate": "2021-03-24" }, "r163": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "33", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2021-03-24" }, "r164": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "34", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_34&doctype=Standard", "URIDate": "2021-03-24" }, "r165": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "9", "Paragraph": "7.2.34", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2021-en-r&anchor=para_7.2.34&doctype=Standard", "URIDate": "2021-03-24" }, "r166": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "113", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2021-03-24" }, "r167": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "124", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_124&doctype=Standard", "URIDate": "2021-03-24" }, "r168": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "125", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_125&doctype=Standard", "URIDate": "2021-03-24" }, "r169": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "127", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_127&doctype=Standard", "URIDate": "2021-03-24" }, "r17": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_a&doctype=Standard", "URIDate": "2021-03-24" }, "r170": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "128", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_128_a_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r171": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "128", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_128_a&doctype=Standard", "URIDate": "2021-03-24" }, "r172": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "C32", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_C32&doctype=Appendix&subtype=C", "URIDate": "2021-03-24" }, "r173": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "9", "Paragraph": "7.2.42", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2021-en-r&anchor=para_7.2.42&doctype=Standard", "URIDate": "2021-03-24" }, "r174": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective on first application of IFRS 9", "Number": "4", "Paragraph": "39L", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2021-en-b&anchor=para_39L_b&doctype=Standard", "URIDate": "2021-03-24" }, "r175": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective on first application of IFRS 9", "Number": "4", "Paragraph": "39L", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2021-en-b&anchor=para_39L_e&doctype=Standard", "URIDate": "2021-03-24" }, "r176": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "4", "Paragraph": "39G", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2021-en-b&anchor=para_39G_a&doctype=Standard&book=b", "URIDate": "2021-03-24" }, "r177": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "23", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_23_d&doctype=Standard&book=b", "URIDate": "2021-03-24" }, "r178": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "36", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_36_a&doctype=Standard&book=b", "URIDate": "2021-03-24" }, "r179": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "36", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_36_c&doctype=Standard&book=b", "URIDate": "2021-03-24" }, "r18": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_c&doctype=Standard", "URIDate": "2021-03-24" }, "r180": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "9", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_9_a&doctype=Standard&book=b", "URIDate": "2021-03-24" }, "r181": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "IG24", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG24_a&doctype=Implementation%20Guidance&book=b", "URIDate": "2021-03-24" }, "r182": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r183": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r184": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r185": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r186": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r187": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r188": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r189": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r19": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_e&doctype=Standard", "URIDate": "2021-03-24" }, "r190": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "103", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_103&doctype=Standard", "URIDate": "2021-03-24" }, "r20": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "h", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_h&doctype=Standard", "URIDate": "2021-03-24" }, "r21": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "i", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_i&doctype=Standard", "URIDate": "2021-03-24" }, "r22": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "l", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_l&doctype=Standard", "URIDate": "2021-03-24" }, "r23": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "n", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_n&doctype=Standard", "URIDate": "2021-03-24" }, "r24": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "55", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_55&doctype=Standard", "URIDate": "2021-03-24" }, "r25": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "66", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard", "URIDate": "2021-03-24" }, "r26": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "69", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_69&doctype=Standard", "URIDate": "2021-03-24" }, "r27": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "7", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_7&doctype=Standard", "URIDate": "2021-03-24" }, "r28": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2021-03-24" }, "r29": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2021-03-24" }, "r3": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "104", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_104&doctype=Standard", "URIDate": "2021-03-24" }, "r30": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78&doctype=Standard", "URIDate": "2021-03-24" }, "r31": { "Clause": "iv", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_iv&doctype=Standard", "URIDate": "2021-03-24" }, "r32": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2021-03-24" }, "r33": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_b&doctype=Standard", "URIDate": "2021-03-24" }, "r34": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_a&doctype=Standard", "URIDate": "2021-03-24" }, "r35": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_b&doctype=Standard", "URIDate": "2021-03-24" }, "r36": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_c&doctype=Standard", "URIDate": "2021-03-24" }, "r37": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_a&doctype=Standard", "URIDate": "2021-03-24" }, "r38": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_b&doctype=Standard", "URIDate": "2021-03-24" }, "r39": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_d&doctype=Standard", "URIDate": "2021-03-24" }, "r4": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_a&doctype=Standard", "URIDate": "2021-03-24" }, "r40": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "85", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_85&doctype=Standard", "URIDate": "2021-03-24" }, "r41": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "90", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_90&doctype=Standard", "URIDate": "2021-03-24" }, "r42": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "91", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_91_a&doctype=Standard", "URIDate": "2021-03-24" }, "r43": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "91", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_91_b&doctype=Standard", "URIDate": "2021-03-24" }, "r44": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "92", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_92&doctype=Standard", "URIDate": "2021-03-24" }, "r45": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "99", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_99&doctype=Standard", "URIDate": "2021-03-24" }, "r46": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "IG6", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2021-03-24" }, "r47": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "10", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI", "URIDate": "2021-03-24" }, "r48": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "79", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_79&doctype=Standard", "URIDate": "2021-03-24" }, "r49": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "ab", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_ab&doctype=Standard", "URIDate": "2021-03-24" }, "r5": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_b&doctype=Standard", "URIDate": "2021-03-24" }, "r50": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2021-03-24" }, "r51": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r52": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "g", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2021-03-24" }, "r53": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2021-03-24" }, "r54": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73&doctype=Standard", "URIDate": "2021-03-24" }, "r55": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "142", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_142&doctype=Standard", "URIDate": "2021-03-24" }, "r56": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "21", "Paragraph": "52", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=21&code=ifrs-tx-2021-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2021-03-24" }, "r57": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "21", "Paragraph": "52", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=21&code=ifrs-tx-2021-en-r&anchor=para_52_b&doctype=Standard", "URIDate": "2021-03-24" }, "r58": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "19", "Subparagraph": "f", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_19_f&doctype=Standard", "URIDate": "2021-03-24" }, "r59": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "19", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_19&doctype=Standard", "URIDate": "2021-03-24" }, "r6": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_i&doctype=Standard", "URIDate": "2021-03-24" }, "r60": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Section": "Disclosures", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI", "URIDate": "2021-03-24" }, "r61": { "Clause": "viii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "26", "Paragraph": "35", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=26&code=ifrs-tx-2021-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2021-03-24" }, "r62": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "32", "Paragraph": "34", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=32&code=ifrs-tx-2021-en-r&anchor=para_34&doctype=Standard", "URIDate": "2021-03-24" }, "r63": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "32", "Paragraph": "IE33", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=32&code=ifrs-tx-2021-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2021-03-24" }, "r64": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Paragraph": "66", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard", "URIDate": "2021-03-24" }, "r65": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Paragraph": "67", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_67&doctype=Standard", "URIDate": "2021-03-24" }, "r66": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI", "URIDate": "2021-03-24" }, "r67": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "36", "Paragraph": "126", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_126&doctype=Standard", "URIDate": "2021-03-24" }, "r68": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "36", "Paragraph": "127", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_127&doctype=Standard", "URIDate": "2021-03-24" }, "r69": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "36", "Paragraph": "130", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_130_d_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r7": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r70": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2021-03-24" }, "r71": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "126", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_126&doctype=Standard", "URIDate": "2021-03-24" }, "r72": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "39", "Paragraph": "86", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=39&code=ifrs-tx-2021-en-r&anchor=para_86_b&doctype=Standard", "URIDate": "2021-03-24" }, "r73": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "40", "Paragraph": "32A", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2021-en-r&anchor=para_32A&doctype=Standard", "URIDate": "2021-03-24" }, "r74": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "41", "Paragraph": "50", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=41&code=ifrs-tx-2021-en-r&anchor=para_50&doctype=Standard", "URIDate": "2021-03-24" }, "r75": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "10", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_10&doctype=Standard", "URIDate": "2021-03-24" }, "r76": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "16", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_16_a&doctype=Standard", "URIDate": "2021-03-24" }, "r77": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "16", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_16&doctype=Standard", "URIDate": "2021-03-24" }, "r78": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2021-03-24" }, "r79": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2021-03-24" }, "r8": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r80": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "17", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17&doctype=Standard", "URIDate": "2021-03-24" }, "r81": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "18", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2021-03-24" }, "r82": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "20", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20&doctype=Standard", "URIDate": "2021-03-24" }, "r83": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "25", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_25&doctype=Standard", "URIDate": "2021-03-24" }, "r84": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "28", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_28&doctype=Standard", "URIDate": "2021-03-24" }, "r85": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "31", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_31&doctype=Standard", "URIDate": "2021-03-24" }, "r86": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "35", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35&doctype=Standard", "URIDate": "2021-03-24" }, "r87": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "39", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_39&doctype=Standard", "URIDate": "2021-03-24" }, "r88": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "45", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard", "URIDate": "2021-03-24" }, "r89": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "50", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2021-03-24" }, "r9": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2021-03-24" }, "r90": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "8", "Paragraph": "28", "Subparagraph": "f", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_f_i&doctype=Standard", "URIDate": "2021-03-24" }, "r91": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "8", "Paragraph": "29", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=8&code=ifrs-tx-2021-en-r&anchor=para_29_c_i&doctype=Standard", "URIDate": "2021-03-24" }, "r92": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "8", "Paragraph": "49", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=8&code=ifrs-tx-2021-en-r&anchor=para_49_b_i&doctype=Standard", "URIDate": "2021-03-24" }, "r93": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2021-03-24" }, "r94": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2021-03-24" }, "r95": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2021-03-24" }, "r96": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r97": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B10", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r98": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r99": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" } }, "version": "2.1" }